


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:52:06Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406685" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406685</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>aac</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="iso-abbrev">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="pmc-domain-id">82</journal-id><journal-id journal-id-type="pmc-domain">aac</journal-id><journal-id journal-id-type="publisher-id">aac</journal-id><journal-title-group><journal-title>Antimicrobial Agents and Chemotherapy</journal-title></journal-title-group><issn pub-type="ppub">0066-4804</issn><issn pub-type="epub">1098-6596</issn><publisher><publisher-name>American Society for Microbiology (ASM)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406685</article-id><article-id pub-id-type="pmcid-ver">PMC12406685.1</article-id><article-id pub-id-type="pmcaid">12406685</article-id><article-id pub-id-type="pmcaiid">12406685</article-id><article-id pub-id-type="pmid">40801835</article-id><article-id pub-id-type="doi">10.1128/aac.00331-25</article-id><article-id pub-id-type="publisher-id">aac00331-25</article-id><article-id pub-id-type="publisher-id">aac.00331-25</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject></subj-group><subj-group subj-group-type="biological-terms"><compound-subject><compound-subject-part content-type="code">parasitology</compound-subject-part><compound-subject-part content-type="label">Parasitology</compound-subject-part></compound-subject></subj-group></article-categories><title-group><article-title>Thiazole substitution of a labile amide bond&#8212;a new option toward antiplasmodial pantothenamide-mimics</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="X">Xiangning</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chu</surname><given-names initials="A">Annica</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nekouei</surname><given-names initials="M">Mina</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lan</surname><given-names initials="CB">Chunling Blue</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pierret</surname><given-names initials="A">Alexandre</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0933-7956</contrib-id><name name-style="western"><surname>Auclair</surname><given-names initials="K">Karine</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="cor1" ref-type="corresp"/><email>k.auclair@mcgill.ca</email></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3345-8440</contrib-id><name name-style="western"><surname>Saliba</surname><given-names initials="KJ">Kevin J.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor2" ref-type="corresp"/><email>kevin.saliba@anu.edu.au</email></contrib><aff id="aff1"><label>1</label><institution-wrap><institution>Research School of Biology, Australian National University</institution><institution-id institution-id-type="ringgold">98471</institution-id><institution-id institution-id-type="ror">https://ror.org/019wvm592</institution-id></institution-wrap>, <city>Canberra</city>, <state>Australian Capital Territory</state>, <country>Australia</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution>Department of Chemistry, McGill University</institution><institution-id institution-id-type="ringgold">242124</institution-id><institution-id institution-id-type="ror">https://ror.org/01pxwe438</institution-id></institution-wrap>, <city>Montreal</city>, <state>Qu&#233;bec</state>, <country>Canada</country></aff></contrib-group><contrib-group><contrib contrib-type="editor"><role>Editor</role><name name-style="western"><surname>Odom John</surname><given-names initials="A">Audrey</given-names></name><aff><institution-wrap><institution>The Children's Hospital of Philadelphia</institution></institution-wrap>, <city>Philadelphia</city>, <state>Pennsylvania</state>, <country>USA</country></aff></contrib></contrib-group><author-notes><corresp id="cor1">Address correspondence to Karine Auclair, <email xlink:href="mailto:k.auclair@mcgill.ca">k.auclair@mcgill.ca</email></corresp><corresp id="cor2">Address correspondence to Kevin J. Saliba, <email xlink:href="mailto:kevin.saliba@anu.edu.au">kevin.saliba@anu.edu.au</email></corresp><fn fn-type="COI-statement"><p>The authors declare no conflict of interest.</p></fn></author-notes><pub-date publication-format="electronic" date-type="collection"><month>9</month><year>2025</year></pub-date><pub-date date-type="pub" publication-format="electronic"><day>13</day><month>8</month><year>2025</year></pub-date><volume>69</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">496152</issue-id><elocation-id>e00331-25</elocation-id><history><date date-type="received"><day>27</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>12</day><month>5</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>13</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 Liu et al.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Liu et al.</copyright-holder><ali:free_to_read start_date="2025-08-13"/><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="aac.00331-25.pdf"/><self-uri content-type="pdf" xlink:href="aac.00331-25.pdf"/><abstract abstract-type="primary"><title>ABSTRACT</title><p>The emergence and spread of artemisinin-partial resistant, malaria-causing <italic toggle="yes">Plasmodium falciparum</italic> provide the impetus for developing novel antimalarials. Pantothenamides are potent inhibitors of malaria parasite proliferation; however, their clinical use is hindered by pantetheinase-mediated degradation in human serum. Here, we report the synthesis and biological activity of a series of pantothenamide-mimics in which the thiazole ring replaces the labile amide bond with various orientations. Out of 23 novel compounds generated and tested in the presence of pantetheinase, several display sub-micromolar antiplasmodial activity <italic toggle="yes">in vitro</italic>. A selection of compounds was studied in more detail, and CoA biosynthesis and/or utilization pathways were confirmed to be the target. Toxicity to human cells was not observed. Kinetic studies identified the selected compounds as substrates of the <italic toggle="yes">Hs</italic>PanK3 enzyme, but with much lower affinity compared to that of the natural substrate pantothenate. The most potent thiazole-bearing antiplasmodial compound was found to bind to <italic toggle="yes">Pf</italic>PanK with a 120-fold higher affinity compared to <italic toggle="yes">Hs</italic>PanK, highlighting excellent selectivity, not only against the key first enzyme in the CoA biosynthesis pathway but also at the whole-cell level. In conclusion, thiazole substitution of the labile amide bond represents a promising avenue for developing antimalarial pantothenamide-mimics.</p></abstract><kwd-group><title>KEYWORDS</title><kwd>malaria</kwd><kwd>antimalarial agents</kwd><kwd><italic toggle="yes">Plasmodium falciparum</italic></kwd><kwd>drug synthesis</kwd><kwd>drug targets</kwd><kwd>coenzyme A</kwd></kwd-group><funding-group specific-use="FundRef"><award-group award-type="grant" id="award-1"><funding-source><institution-wrap><institution>Canadian Institute of Health Research</institution></institution-wrap></funding-source><award-id>PJT186220</award-id><principal-award-recipient><name name-style="western"><surname>Auclair</surname><given-names>Karine</given-names></name><name name-style="western"><surname>Saliba</surname><given-names>Kevin J.</given-names></name></principal-award-recipient></award-group></funding-group><counts><count count="2" count-type="supplementary-material"/><count count-type="authors" count="7"/><fig-count count="7"/><table-count count="2"/><equation-count count="0"/><ref-count count="103"/><page-count count="21"/><word-count count="12345"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>September 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>INTRODUCTION</title><p>Malaria is a lethal infectious disease caused by unicellular protozoan parasites of the genus <italic toggle="yes">Plasmodium</italic>. Despite remarkable progress toward malaria elimination, the 2024 World Malaria Report estimated 263 million new cases and 597,000 deaths worldwide attributed to malaria in 2023 (<xref rid="B1" ref-type="bibr">1</xref>). Of the six <italic toggle="yes">Plasmodium</italic> species that infect humans (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>), <italic toggle="yes">Plasmodium falciparum</italic> is responsible for most of the infections and deaths in the sub-Saharan African region (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B4" ref-type="bibr">4</xref>). Currently, artemisinin-based combination therapies (ACT) are the first-line treatment for uncomplicated <italic toggle="yes">P. falciparum</italic> malaria in all areas. However, the emergence of ACT-partial resistant parasites and their rapid spread across the globe (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>), including in recent cases of severe malaria in Africa (<xref rid="B7" ref-type="bibr">7</xref>), threatens the efficacy of ACT, thus hampering the treatment of the disease. To increase the repertoire of available therapeutics, the discovery of new antimalarials with unique mechanisms of action and no cross-resistance with existing drugs is essential (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>).</p><p>Water-soluble vitamin B<sub>5</sub> (pantothenate) is an essential substance required by the intraerythrocytic stage parasites. Pantothenate is the precursor to coenzyme A (CoA), a cofactor involved in many metabolic processes (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>). Pantothenate utilization and CoA biosynthesis in <italic toggle="yes">P. falciparum</italic> have been extensively studied (<xref rid="B12" ref-type="bibr">12</xref><xref rid="B13" ref-type="bibr">&#8211;</xref><xref rid="B15" ref-type="bibr">15</xref>) and have been identified as viable drug targets in the parasite (<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B17" ref-type="bibr">17</xref>). First synthesized by Clifton et al. in 1970 (<xref rid="B18" ref-type="bibr">18</xref>), pantothenamides were initially reported to exhibit antibacterial activity (<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B19" ref-type="bibr">19</xref>), with their antiplasmodial activity demonstrated by Spry et al. in 2013 (<xref rid="B20" ref-type="bibr">20</xref>). In <italic toggle="yes">P. falciparum</italic>, pantothenamides are first phosphorylated by pantothenate kinase (PanK) and further metabolized by phosphopantetheine adenylyltransferase (PPAT) and dephospho-CoA kinase (DPCK) to generate the corresponding antiplasmodial CoA antimetabolite (<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B22" ref-type="bibr">22</xref>). Despite their high potency and low cytotoxicity <italic toggle="yes">in vitro</italic>, the clinical use of pantothenamides, such as the benchmark compound N5-Pan, is hindered due to their instability <italic toggle="yes">in vivo</italic> (<xref rid="F1" ref-type="fig">Fig. 1A and B</xref>) (<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B23" ref-type="bibr">23</xref>). The pantetheinases in human serum readily hydrolyze the amide depicted in red in <xref rid="F1" ref-type="fig">Fig. 1A</xref>, resulting in the rapid breakdown of pantothenamides. To overcome this issue, our research group and others have employed various structural modifications, including alterations at the <italic toggle="yes">gem</italic>-dimethyl group (<xref rid="B24" ref-type="bibr">24</xref><xref rid="B25" ref-type="bibr">&#8211;</xref><xref rid="B26" ref-type="bibr">26</xref>), the pantoyl primary alcohol (<xref rid="B27" ref-type="bibr">27</xref>), &#946;-alanine (<xref rid="B27" ref-type="bibr">27</xref><xref rid="B28" ref-type="bibr">&#8211;</xref><xref rid="B30" ref-type="bibr">30</xref>), and the labile amide (<xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B31" ref-type="bibr">31</xref><xref rid="B32" ref-type="bibr">&#8211;</xref><xref rid="B36" ref-type="bibr">36</xref>) moieties of pantothenamides. In particular, inversion of the labile amide bond has led to very promising compounds, including the discovery of a preclinical pantothenamide-mimic MMV693183 (<xref rid="F1" ref-type="fig">Fig. 1B</xref>) (<xref rid="B36" ref-type="bibr">36</xref>). These findings motivated our search for new pantetheinase-resistant pantothenamides.</p><fig position="float" fig-type="figure" id="F1" orientation="portrait"><label>Fig 1</label><caption><p>(<bold>A</bold>) Pantothenamides are readily hydrolyzed by serum pantetheinases to yield pantothenate and an amine. The pantetheinase-sensitive amide bond is shown in red. R is commonly an aliphatic or aromatic moiety. (<bold>B</bold>) Structures of N5-Pan, reverse N5-Pan and the preclinical pantothenamide-mimic MMV693183 with the labile amide bond reversed. The pantoyl moiety is drawn in green. (<bold>C</bold>) Structures of compounds <bold>i</bold> to <bold>v</bold> with their respective 50% inhibitory concentrations (IC<sub>50</sub> values) measured against intraerythrocytic <italic toggle="yes">P. falciparum</italic> in the presence of pantetheinases. Side chains are shown in blue. (<bold>D</bold>) Examples of thiazole-containing pharmaceuticals. Thiazoles are highlighted in maroon.</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.00331-25.f001.jpg"><alt-text>Chemical diagrams and IC_50 data present pantetheinase substrate cleavage, N5-Pan analogs, potent inhibitors, and drugs containing thiazole moieties, highlighting structural motifs and inhibitory activity against pantetheinase targets.</alt-text></graphic></fig><p>We have recently focused on replacing the labile amide with heterocycles (<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B35" ref-type="bibr">35</xref>), which are privileged scaffolds in medicinal chemistry. More than 80% of marketed drugs contain at least one heterocyclic fragment in their structure (<xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B38" ref-type="bibr">38</xref>). They can participate in diverse secondary interactions due to the presence of the heteroatoms and nuanced aromaticity and can significantly affect the physicochemical properties of the molecules (<xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B39" ref-type="bibr">39</xref>). Previously, we reported a series of analogs in which the labile amide group is replaced with diverse heterocycles, resulting in pantothenamide analogs that exhibited pantetheinase resistance and enhanced potency (<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B35" ref-type="bibr">35</xref>). In particular, the 1,4-substituted 1,2,3-triazole with a pentyl or hexyl side chain (compounds <bold>i</bold> and <bold>ii</bold>, <xref rid="F1" ref-type="fig">Fig. 1C</xref>), the 3,5-substituted 1,2-isoxazole with a butyl or pentyl chain (compounds <bold>iii</bold> and <bold>iv</bold>), as well as the 2,5-substituted 1,3,4-thiadiazole (compound <bold>v</bold>), were particularly potent.</p><p>Sulfur is a ubiquitous heteroatom in medicinal chemistry (<xref rid="B40" ref-type="bibr">40</xref>), and a variety of sulfur-containing scaffolds are employed in the pharmaceutical industry (<xref rid="B41" ref-type="bibr">41</xref>). Sulfur is known to serve as an excellent &#963;-hole to host electrons from adjacent donors, which has a profound impact on conformational stabilization. This can greatly reduce entropic penalty during target engagement (<xref rid="B39" ref-type="bibr">39</xref>, <xref rid="B42" ref-type="bibr">42</xref>), thus enhancing potency. One of the most prevalent scaffolds in this category is the thiazole (<xref rid="B43" ref-type="bibr">43</xref>). Examples of thiazole-containing pharmaceuticals (<xref rid="F1" ref-type="fig">Fig. 1D</xref>) include ravuconazole (antifungal) (<xref rid="B44" ref-type="bibr">44</xref>), nitazoxanide (antiparasitic) (<xref rid="B45" ref-type="bibr">45</xref>), cefotaxime (antibacterial) (<xref rid="B46" ref-type="bibr">46</xref>), ixabepilone (anticancer) (<xref rid="B47" ref-type="bibr">47</xref>), as well as ritonavir (antiviral) (<xref rid="B48" ref-type="bibr">48</xref>). Despite the high prevalence of sulfur in medicines, sulfur-containing pantothenamides are currently underdeveloped. To date, several such compounds have been reported (<xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B35" ref-type="bibr">35</xref>), but few have had a sulfur-containing heterocycle (<xref rid="B35" ref-type="bibr">35</xref>).</p><p>Herein, we describe the synthesis, antiplasmodial activity, target determination, and toxicity profile of novel pantothenamide-mimics containing thiazoles. In addition, we report the kinetic analysis of a selection of these compounds using recombinantly expressed and purified human PanK3 (<italic toggle="yes">Hs</italic>PanK3) as well as the <italic toggle="yes">P. falciparum</italic> PanK (<italic toggle="yes">Pf</italic>PanK) in parasite lysates.</p></sec><sec sec-type="results" id="s2"><title>RESULTS</title><sec id="s2-1"><title>Synthesis</title><p>Considering that a one-carbon linker was reported to be preferred between the pantoyl (in green in <xref rid="F1" ref-type="fig">Fig. 1B</xref>) and the heterocyclic moieties in pantothenamide-mimics containing a triazole or isoxazole in place of the labile amide bond (<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B35" ref-type="bibr">35</xref>), we elected to synthesize thiazole analogs that harbor a one-carbon linker. <xref rid="F2" ref-type="fig">Figure 2</xref> illustrates the synthetic route for compounds <bold>1a</bold>&#8211;<bold>1e</bold> containing 2-aminomethyl-4-substituted thiazoles. Acid-catalyzed monobromination of the methyl ketones was first achieved to access the bromoketone fragments <bold>1.1a</bold>&#8211;<bold>1.1e</bold> for Hantzsch thiazole synthesis. The thioamide counterpart was synthesized through an amidation-thiation sequence from Boc-glycine methyl ester. Traditional Hantzsch thiazole synthesis between <bold>1.3</bold> and <bold>1.1a</bold>&#8211;<bold>1.1e</bold> generated the thiazole rings. Boc deprotection, followed by aminolysis of D-pantolactone, yielded the target compounds <bold>1a</bold>&#8211;<bold>1e</bold>. Notably, the aminolysis conditions under microwave irradiation reported before (<xref rid="B31" ref-type="bibr">31</xref>) were not successful here, as decomposition was observed during the reaction. Instead, strictly thermal conditions were employed to avoid decomposition of the starting materials.</p><fig position="float" fig-type="figure" id="F2" orientation="portrait"><label>Fig 2</label><caption><p>Synthetic route for compounds <bold>1a</bold>&#8211;<bold>1e</bold>. Boc: <italic toggle="yes">tert</italic>-butyloxycarbonyl; DCM: dichloromethane; LR, Lawesson&#8217;s reagent; rt: room temperature; TEA: triethylamine; TFA: trifluoroacetic acid; THF: tetrahydrofuran.</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.00331-25.f002.jpg"><alt-text>Reaction scheme presents multistep synthesis of pantothenamide analogs 1a&#8211;1e, involving thiazole formation from &#946;-amino amide intermediates, followed by deprotection and coupling with D-pantolactone, with variable R-group side chains.</alt-text></graphic></fig><p>A similar approach was adopted for the synthesis of thiazole derivatives with the reverse ring orientation, that is, 4-aminomethyl-2-substituted thiazoles <bold>2a</bold>&#8211;<bold>2h</bold> (<xref rid="F3" ref-type="fig">Fig. 3</xref>). Substitution followed by monobromination afforded the bromoketones with a phthalimide-protected amino handle (<bold>2.2</bold>). The same amidation-thiation process as above was used to access the thioamides <bold>2.4a</bold>&#8211;<bold>2.4h</bold>, starting from various acyl chlorides. Likewise, Hantzsch thiazole synthesis led to the thiazole core. Finally, removal of the phthalimide protecting group, followed by aminolysis of D-pantolactone, afforded the target compounds.</p><fig position="float" fig-type="figure" id="F3" orientation="portrait"><label>Fig 3</label><caption><p>Synthetic route for compounds <bold>2a</bold>&#8211;<bold>2h</bold>. DMF: <italic toggle="yes">N, N</italic>-dimethylformamide; LR: Lawesson&#8217;s reagent; PhthK: potassium phthalimide; PyH: pyridine; rt: room temperature; TEA: triethylamine; THF: tetrahydrofuran.</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.00331-25.f003.jpg"><alt-text>Reaction scheme of modular synthesis of thiazole-linked pantothenamide analogs 2a&#8211;2h via amide formation, Lawesson&#8217;s reagent thionation, cyclization, hydrazinolysis, and coupling with D-pantolactone, incorporating eight distinct R-group substituents.</alt-text></graphic></fig><p>For the synthesis of pantothenamide-mimics with 5-aminomethyl-2-substituted thiazoles (<xref rid="F4" ref-type="fig">Fig. 4</xref>), two different routes were utilized. For synthetic targets harboring a thiazole with alkyl substituents (<bold>3a</bold>&#8211;<bold>3e</bold>), decoration of the thiazole was adopted. Thus, Negishi coupling employing 2-bromo-5-cyanothiazole successfully furnished the alkyl-substituted thiazole. Reduction of the nitrile afforded amines <bold>3.2a</bold>&#8211;<bold>3.2e</bold>, which were subjected to a recently published method (<xref rid="B49" ref-type="bibr">49</xref>) for catalytic D-pantolactone aminolysis to generate the corresponding products. To prepare compounds with an aryl-substituted thiazole (<bold>3f</bold>&#8211;<bold>3j</bold>), a reported methodology was followed to access the ring (<xref rid="B50" ref-type="bibr">50</xref>). First, the amidation-thiation approach was again utilized to assemble the thioamides <bold>3.4f</bold>&#8211;<bold>3.4j</bold>, which underwent <italic toggle="yes">N</italic>-bromosuccinimide-promoted cyclization-oxidation to afford the thiazole core with a bromide handle. Gabriel synthesis converted the bromide handles to amines <bold>3.7f</bold>&#8211;<bold>3.7j</bold>, which were subjected to the same thermal aminolysis conditions as above to yield compound <bold>3f</bold>&#8211;<bold>3j</bold>.</p><fig position="float" fig-type="figure" id="F4" orientation="portrait"><label>Fig 4</label><caption><p>Synthetic route to compounds <bold>3a</bold>&#8211;<bold>3j</bold>. DCM: dichloromethane; DMF: <italic toggle="yes">N, N</italic>-dimethylformamide; LR: Lawesson&#8217;s reagent; NBS: <italic toggle="yes">N</italic>-bromosuccinimide; PhthK: potassium phthalimide; rt: room temperature; TBD: 1,5,7-triazabicyclo[4.4.0]dec-5-ene; TEA: triethylamine; THF: tetrahydrofuran.</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.00331-25.f004.jpg"><alt-text>Reaction scheme outlines the synthesis of pantothenamide derivatives 3f&#8211;3j, beginning with Grignard coupling, followed by reduction, amination, coupling with D-pantolactone, and diversified via aryl and alkyl R groups a&#8211;j with yields from 12&#8211;95%.</alt-text></graphic></fig></sec><sec id="s2-2"><title><italic toggle="yes">In vitro</italic> antiplasmodial activity</title><p>The antiplasmodial activity of all synthetic compounds was evaluated against <italic toggle="yes">P. falciparum</italic>. Thiazoles <bold>1a</bold>, <bold>1e</bold>, and <bold>2e</bold> were found to inhibit intraerythrocytic proliferation of <italic toggle="yes">P. falciparum</italic> with IC<sub>50</sub> values in the sub-micromolar range (<xref rid="T1" ref-type="table">Table 1</xref> and <xref rid="SuF1" ref-type="supplementary-material">Fig. S1</xref>). As evident from the overall higher activity of compound series <bold>1</bold> and series <bold>2</bold> relative to series <bold>3</bold>, it can be concluded that a nitrogen atom is preferred between the substituents of the ring, whereas a sulfur atom is beneficial at the other two ring positions. In series <bold>1</bold>, unlike what was previously reported by Howieson et al. (<xref rid="B32" ref-type="bibr">32</xref>) and Guan et al. (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B35" ref-type="bibr">35</xref>) for triazole- and isoxazole-containing analogs, phenethyl and butyl side chains are equally potent (see <bold>1a</bold> and <bold>1e</bold>), consistent with the length of a phenyl ring (2.8 &#197;) (<xref rid="B51" ref-type="bibr">51</xref>) roughly equaling that of a 3-carbon chain (2.5&#8211;2.6 &#197;) (<xref rid="B52" ref-type="bibr">52</xref>). The structure-activity relationships (SARs) reveal that a butyl chain is preferred over a pentyl or a hexyl group, and branching is detrimental. Interestingly, for the 4-aminomethyl-2-substituted thiazole series (<bold>2a</bold>&#8211;<bold>2h</bold>), alkyl chains were no longer preferred. Instead, the phenyl group may be favored (as in <bold>2e</bold>) with a slightly lower IC<sub>50</sub> (0.51 &#181;M) compared to those of <bold>1a</bold> (0.77 &#181;M) and <bold>1e</bold> (0.77 &#181;M), although these did not reach statistical significance at the <italic toggle="yes">P</italic> &#8804; 0.05 level (<italic toggle="yes">P</italic> = 0.059 and 0.052, respectively). Moreover, the addition of substituents to the phenyl ring was disadvantageous irrespective of the position, with larger substituents showing a stronger effect, as observed for <italic toggle="yes">para</italic>-chlorine (3.1 &#181;M for <bold>2f</bold>, <italic toggle="yes">P</italic> = 0.0006), <italic toggle="yes">para</italic>-CF<sub>3</sub> (57 &#181;M for <bold>2g</bold>, <italic toggle="yes">P</italic> &lt; 0.0001), and <italic toggle="yes">meta</italic>-trifluoromethyl (21 &#181;M for <bold>2h</bold>, <italic toggle="yes">P</italic> &lt; 0.0001). A similar trend was observed for the 5-aminomethyl-2-substituted thiazole series (<bold>3a</bold>&#8211;<bold>3j</bold>), with the preference for an unsubstituted phenyl group (<bold>3f</bold>) over alkyl groups, despite the overall lower potency of this series. In contrast to what was observed for <bold>2f</bold>&#8211;<bold>2h</bold>, <bold>3j</bold> is more potent than <bold>3h</bold>&#8211;<bold>3i</bold>, implying that a <italic toggle="yes">meta</italic>-trifluoromethyl group (11 &#181;M for <bold>3j</bold>) is favored over most <italic toggle="yes">para</italic>-substituent group (14&#8211;46 &#181;M for <bold>3h</bold>&#8211;<bold>3i</bold>, <italic toggle="yes">P</italic> &#8804; 0.0038) on the phenyl ring in this series.</p><table-wrap position="float" id="T1" orientation="portrait"><label>TABLE 1</label><caption><p>Effect of the compounds on the proliferation of intraerythrocytic <italic toggle="yes">P. falciparum</italic>, human foreskin fibroblasts (HFF), and human hepatoblastoma cells (HepG2) at different pantothenate concentrations</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="center" valign="top" colspan="2" rowspan="1">Compound</th><th align="left" valign="top" colspan="1" rowspan="1">IC<sub>50</sub> (&#181;M) against <italic toggle="yes">Pf</italic> at 1 &#181;M Pan<xref rid="T1_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></th><th align="left" valign="top" colspan="1" rowspan="1">IC<sub>50</sub> (&#181;M) against <italic toggle="yes">Pf</italic> at 100 &#181;M Pan<xref rid="T1_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></th><th align="left" valign="top" colspan="1" rowspan="1">Proliferation (%) of HFF with 200 &#181;M<break/>Cpd and 16.8 &#181;M Pan<xref rid="T1_FN3" ref-type="table-fn"><sup><italic toggle="yes">c</italic></sup></xref></th><th align="left" valign="top" colspan="1" rowspan="1">Proliferation (%) of HepG2 with 200 &#181;M Cpd and 1 &#181;M Pan<xref rid="T1_FN4" ref-type="table-fn"><sup><italic toggle="yes">d</italic></sup></xref></th></tr></thead><tbody><tr><td align="left" valign="top" colspan="1" rowspan="1">1a</td><td align="left" valign="top" colspan="1" rowspan="1">
<inline-graphic xlink:href="aac.00331-25.inline001.jpg"/>
</td><td align="center" valign="top" colspan="1" rowspan="1">
<bold>0.77 &#177; 0.10</bold>
</td><td align="center" valign="top" colspan="1" rowspan="1">&gt; 6.25</td><td align="center" valign="top" colspan="1" rowspan="1">100 &#177; 1</td><td align="center" valign="top" colspan="1" rowspan="1">71 &#177; 11</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">1b</td><td align="left" valign="top" colspan="1" rowspan="1">
<inline-graphic xlink:href="aac.00331-25.inline002.jpg"/>
</td><td align="center" valign="top" colspan="1" rowspan="1">2.9 &#177; 0.2</td><td align="center" valign="top" colspan="1" rowspan="1">-<xref rid="T1_FN5" ref-type="table-fn"><sup><italic toggle="yes">e</italic></sup></xref></td><td align="center" valign="top" colspan="1" rowspan="1">-</td><td align="center" valign="top" colspan="1" rowspan="1">-</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">1c</td><td align="left" valign="top" colspan="1" rowspan="1">
<inline-graphic xlink:href="aac.00331-25.inline003.jpg"/>
</td><td align="center" valign="top" colspan="1" rowspan="1">2.3 &#177; 0.2</td><td align="center" valign="top" colspan="1" rowspan="1">&gt; 25</td><td align="center" valign="top" colspan="1" rowspan="1">97 &#177; 4</td><td align="center" valign="top" colspan="1" rowspan="1">62 &#177; 7</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">1d</td><td align="left" valign="top" colspan="1" rowspan="1">
<inline-graphic xlink:href="aac.00331-25.inline004.jpg"/>
</td><td align="center" valign="top" colspan="1" rowspan="1">4.3 &#177; 0.4</td><td align="center" valign="top" colspan="1" rowspan="1">-</td><td align="center" valign="top" colspan="1" rowspan="1">-</td><td align="center" valign="top" colspan="1" rowspan="1">-</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">1e</td><td align="left" valign="top" colspan="1" rowspan="1">
<inline-graphic xlink:href="aac.00331-25.inline005.jpg"/>
</td><td align="center" valign="top" colspan="1" rowspan="1">
<bold>0.77 &#177; 0.09</bold>
</td><td align="center" valign="top" colspan="1" rowspan="1">&gt; 12.5</td><td align="center" valign="top" colspan="1" rowspan="1">101 &#177; 2</td><td align="center" valign="top" colspan="1" rowspan="1">55 &#177; 1</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">2a</td><td align="left" valign="top" colspan="1" rowspan="1">
<inline-graphic xlink:href="aac.00331-25.inline006.jpg"/>
</td><td align="center" valign="top" colspan="1" rowspan="1">5.6 &#177; 0.2</td><td align="center" valign="top" colspan="1" rowspan="1">-</td><td align="center" valign="top" colspan="1" rowspan="1">-</td><td align="center" valign="top" colspan="1" rowspan="1">-</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">2b</td><td align="left" valign="top" colspan="1" rowspan="1">
<inline-graphic xlink:href="aac.00331-25.inline007.jpg"/>
</td><td align="center" valign="top" colspan="1" rowspan="1">5.2 &#177; 0.6</td><td align="center" valign="top" colspan="1" rowspan="1">-</td><td align="center" valign="top" colspan="1" rowspan="1">-</td><td align="center" valign="top" colspan="1" rowspan="1">-</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">2c</td><td align="left" valign="top" colspan="1" rowspan="1">
<inline-graphic xlink:href="aac.00331-25.inline008.jpg"/>
</td><td align="center" valign="top" colspan="1" rowspan="1">2.4 &#177; 0.2</td><td align="center" valign="top" colspan="1" rowspan="1">&gt; 25</td><td align="center" valign="top" colspan="1" rowspan="1">101 &#177; 2</td><td align="center" valign="top" colspan="1" rowspan="1">93 &#177; 2</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">2d</td><td align="left" valign="top" colspan="1" rowspan="1">
<inline-graphic xlink:href="aac.00331-25.inline009.jpg"/>
</td><td align="center" valign="top" colspan="1" rowspan="1">6.5 &#177; 0.1</td><td align="center" valign="top" colspan="1" rowspan="1">-</td><td align="center" valign="top" colspan="1" rowspan="1">-</td><td align="center" valign="top" colspan="1" rowspan="1">-</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">2e</td><td align="left" valign="top" colspan="1" rowspan="1">
<inline-graphic xlink:href="aac.00331-25.inline010.jpg"/>
</td><td align="center" valign="top" colspan="1" rowspan="1">
<bold>0.51 &#177; 0.02</bold>
</td><td align="center" valign="top" colspan="1" rowspan="1">&gt; 6.25</td><td align="center" valign="top" colspan="1" rowspan="1">100 &#177; 1</td><td align="center" valign="top" colspan="1" rowspan="1">91 &#177; 4</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">2f</td><td align="left" valign="top" colspan="1" rowspan="1">
<inline-graphic xlink:href="aac.00331-25.inline011.jpg"/>
</td><td align="center" valign="top" colspan="1" rowspan="1">3.1 &#177; 0.3</td><td align="center" valign="top" colspan="1" rowspan="1">-</td><td align="center" valign="top" colspan="1" rowspan="1">-</td><td align="center" valign="top" colspan="1" rowspan="1">-</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">2g</td><td align="left" valign="top" colspan="1" rowspan="1">
<inline-graphic xlink:href="aac.00331-25.inline012.jpg"/>
</td><td align="center" valign="top" colspan="1" rowspan="1">57 &#177; 2</td><td align="center" valign="top" colspan="1" rowspan="1">-</td><td align="center" valign="top" colspan="1" rowspan="1">-</td><td align="center" valign="top" colspan="1" rowspan="1">-</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">2h</td><td align="left" valign="top" colspan="1" rowspan="1">
<inline-graphic xlink:href="aac.00331-25.inline013.jpg"/>
</td><td align="center" valign="top" colspan="1" rowspan="1">21 &#177; 1</td><td align="center" valign="top" colspan="1" rowspan="1">-</td><td align="center" valign="top" colspan="1" rowspan="1">-</td><td align="center" valign="top" colspan="1" rowspan="1">-</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">3a</td><td align="left" valign="top" colspan="1" rowspan="1">
<inline-graphic xlink:href="aac.00331-25.inline014.jpg"/>
</td><td align="center" valign="top" colspan="1" rowspan="1">11 &#177; 1</td><td align="center" valign="top" colspan="1" rowspan="1">-</td><td align="center" valign="top" colspan="1" rowspan="1">-</td><td align="center" valign="top" colspan="1" rowspan="1">-</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">3b</td><td align="left" valign="top" colspan="1" rowspan="1">
<inline-graphic xlink:href="aac.00331-25.inline015.jpg"/>
</td><td align="center" valign="top" colspan="1" rowspan="1">12 &#177; 1</td><td align="center" valign="top" colspan="1" rowspan="1">-</td><td align="center" valign="top" colspan="1" rowspan="1">-</td><td align="center" valign="top" colspan="1" rowspan="1">-</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">3c</td><td align="left" valign="top" colspan="1" rowspan="1">
<inline-graphic xlink:href="aac.00331-25.inline016.jpg"/>
</td><td align="center" valign="top" colspan="1" rowspan="1">35 &#177; 2</td><td align="center" valign="top" colspan="1" rowspan="1">-</td><td align="center" valign="top" colspan="1" rowspan="1">-</td><td align="center" valign="top" colspan="1" rowspan="1">-</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">3d</td><td align="left" valign="top" colspan="1" rowspan="1">
<inline-graphic xlink:href="aac.00331-25.inline017.jpg"/>
</td><td align="center" valign="top" colspan="1" rowspan="1">16 &#177; 1</td><td align="center" valign="top" colspan="1" rowspan="1">-</td><td align="center" valign="top" colspan="1" rowspan="1">-</td><td align="center" valign="top" colspan="1" rowspan="1">-</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">3e</td><td align="left" valign="top" colspan="1" rowspan="1">
<inline-graphic xlink:href="aac.00331-25.inline018.jpg"/>
</td><td align="center" valign="top" colspan="1" rowspan="1">44 &#177; 1</td><td align="center" valign="top" colspan="1" rowspan="1">-</td><td align="center" valign="top" colspan="1" rowspan="1">-</td><td align="center" valign="top" colspan="1" rowspan="1">-</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">3f</td><td align="left" valign="top" colspan="1" rowspan="1">
<inline-graphic xlink:href="aac.00331-25.inline019.jpg"/>
</td><td align="center" valign="top" colspan="1" rowspan="1">8.0 &#177; 0.7</td><td align="center" valign="top" colspan="1" rowspan="1">&gt; 50</td><td align="center" valign="top" colspan="1" rowspan="1">100 &#177; 1</td><td align="center" valign="top" colspan="1" rowspan="1">89 &#177; 2</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">3g</td><td align="left" valign="top" colspan="1" rowspan="1">
<inline-graphic xlink:href="aac.00331-25.inline020.jpg"/>
</td><td align="center" valign="top" colspan="1" rowspan="1">14 &#177; 2</td><td align="center" valign="top" colspan="1" rowspan="1">-</td><td align="center" valign="top" colspan="1" rowspan="1">-</td><td align="center" valign="top" colspan="1" rowspan="1">-</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">3h</td><td align="left" valign="top" colspan="1" rowspan="1">
<inline-graphic xlink:href="aac.00331-25.inline021.jpg"/>
</td><td align="center" valign="top" colspan="1" rowspan="1">44 &#177; 4</td><td align="center" valign="top" colspan="1" rowspan="1">-</td><td align="center" valign="top" colspan="1" rowspan="1">-</td><td align="center" valign="top" colspan="1" rowspan="1">-</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">3i</td><td align="left" valign="top" colspan="1" rowspan="1">
<inline-graphic xlink:href="aac.00331-25.inline022.jpg"/>
</td><td align="center" valign="top" colspan="1" rowspan="1">46 &#177; 6</td><td align="center" valign="top" colspan="1" rowspan="1">-</td><td align="center" valign="top" colspan="1" rowspan="1">-</td><td align="center" valign="top" colspan="1" rowspan="1">-</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">3j</td><td align="left" valign="top" colspan="1" rowspan="1">
<inline-graphic xlink:href="aac.00331-25.inline023.jpg"/>
</td><td align="center" valign="top" colspan="1" rowspan="1">11 &#177; 1</td><td align="center" valign="top" colspan="1" rowspan="1">-</td><td align="center" valign="top" colspan="1" rowspan="1">-</td><td align="center" valign="top" colspan="1" rowspan="1">-</td></tr></tbody></table><table-wrap-foot><fn id="T1_FN1"><label>
<sup>
<italic toggle="yes">a</italic>
</sup>
</label><p>Antiplasmodial IC<sub>50</sub> values (&#181;M) were determined against the intraerythrocytic stage of <italic toggle="yes">P. falciparum</italic> (<italic toggle="yes">Pf</italic>) in RPMI-1640 medium containing 1 &#181;M (the normal concentration present in RPMI-1640). IC<sub>50</sub> values that are sub-micromolar are highlighted in bold.</p></fn><fn id="T1_FN2"><label>
<sup>
<italic toggle="yes">b</italic>
</sup>
</label><p>Antiplasmodial IC<sub>50</sub> values (&#181;M) were determined against the intraerythrocytic stage of <italic toggle="yes">P. falciparum</italic> (<italic toggle="yes">Pf</italic>) in RPMI-1640 medium containing 100 &#181;M pantothenate.</p></fn><fn id="T1_FN3"><label>
<sup>
<italic toggle="yes">c</italic>
</sup>
</label><p>Human foreskin fibroblast (HFF) proliferation (%) in the presence of 200 &#181;M test compound (Cpd) was determined in DMEM medium containing 16.8 &#181;M pantothenate (the normal concentration present in DMEM).</p></fn><fn id="T1_FN4"><label>
<sup>
<italic toggle="yes">d</italic>
</sup>
</label><p>Human hepatoblastoma cell (HepG2) proliferation (%) in the presence of 200 &#181;M test compound (Cpd) was determined in RPMI-1640 medium containing 1 &#181;M pantothenate. Antiplasmodial data are averaged from three independent experiments, each performed in triplicate, and errors represent SEM. HFF and HepG2 proliferation data are averaged from two independent experiments, each performed in triplicate, and errors represent range/2. </p></fn><fn id="T1_FN5"><label>
<sup>
<italic toggle="yes">e</italic>
</sup>
</label><p>- indicates not determined.</p></fn></table-wrap-foot></table-wrap><p>Previously, we have shown that the mechanism of action of heterocyclic pantothenamide-mimics against <italic toggle="yes">P. falciparum</italic> involves bioactivation by PanK, PPAT, and DPCK, resulting in the formation of the corresponding CoA antimetabolites that are hypothesized to inhibit CoA-utilizing enzymes (<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B35" ref-type="bibr">35</xref>), as have been previously observed for reverse pantothenamide-mimics (<xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B36" ref-type="bibr">36</xref>). To investigate whether the newly synthesized thiazole derivatives exert their antiplasmodial activity <italic toggle="yes">via</italic> a mechanism that is competitive with pantothenate, the substrate of PanK, we evaluated the antiplasmodial activity of a selection of compounds (<bold>1a</bold>, <bold>1c</bold>, <bold>1e</bold>, <bold>2c</bold>, <bold>2e</bold>, and <bold>3f</bold>) against <italic toggle="yes">P. falciparum</italic> in the presence of a higher concentration of extracellular pantothenate (100 &#181;M, instead of the normal 1 &#181;M that is present in RPMI-1640). Upon adding excess pantothenate, an increase (&gt;6-fold) in IC<sub>50</sub> values was observed for all tested compounds (<xref rid="T1" ref-type="table">Table 1</xref> and <xref rid="SuF1" ref-type="supplementary-material">Fig. S1</xref>), similar to what was previously reported for triazole- and isoxazole-containing pantothenamide analogs (<xref rid="B35" ref-type="bibr">35</xref>), indicating that the thiazole derivatives are also competing with pantothenate, most likely as substrates of <italic toggle="yes">Pf</italic>PanK.</p><p>Subsequently, the effect of those compounds on the proliferation of human foreskin fibroblast (HFF) cells and human hepatoblastoma cells (HepG2) was assessed using the Incucyte Live-Cell Analysis System, allowing automatic capture of cellular changes and assessment of cell proliferation in the presence of each compound. Cycloheximide (10 &#181;M), a potent protein synthesis inhibitor (<xref rid="B53" ref-type="bibr">53</xref>, <xref rid="B54" ref-type="bibr">54</xref>), was used as a positive control, which completely inhibited the proliferation of HFF cells as expected (<xref rid="SuF1" ref-type="supplementary-material">Fig. S2</xref>). By contrast, none of the compounds inhibited the proliferation of the cells at 200 &#181;M, the highest concentration tested, consistent with the compounds being nontoxic to HFF cells (<xref rid="T1" ref-type="table">Table 1</xref> and <xref rid="SuF1" ref-type="supplementary-material">Fig. S2</xref>). For HepG2 cells, proliferation was completely inhibited in the presence of 10 &#181;M of puromycin as expected (<xref rid="SuF1" ref-type="supplementary-material">Fig. S3</xref>) (<xref rid="B55" ref-type="bibr">55</xref>). By contrast, three (<bold>2c</bold>, <bold>2e,</bold> and <bold>3f</bold>) of the six compounds tested were also completely inactive against HepG2 at 200 &#181;M (i.e<italic toggle="yes">.,</italic> as they were against HFF cells) (<xref rid="T1" ref-type="table">Table 1</xref> and <xref rid="SuF1" ref-type="supplementary-material">Fig. S3</xref>). The other three compounds (<bold>1a</bold>, <bold>1c</bold>, and <bold>1e</bold>) showed some low-level toxicity, with only one compound (<bold>1e</bold>) approaching 50% inhibition of proliferation of HepG2 cells at 200 &#181;M (<xref rid="T1" ref-type="table">Table 1</xref> and <xref rid="SuF1" ref-type="supplementary-material">Fig. S3</xref>). It should be noted that the HepG2 toxicity screen was carried out in RPMI-1640 (to more closely match the conditions used in the <italic toggle="yes">P. falciparum</italic> assays), and the small degree of toxicity observed for some of the compounds could be due to the lower concentration (1 &#181;M) of pantothenate in the culture medium compared to that present in DMEM (16.8 &#181;M) used for the HFF experiment, rather than a difference in sensitivity by these different cell lines to the compounds.</p></sec><sec id="s2-3"><title>Compound interaction with <italic toggle="yes">Hs</italic>PanK3 and <italic toggle="yes">Pf</italic>PanK</title><p>Considering the initial involvement of phosphorylation by <italic toggle="yes">Pf</italic>PanK in the mode of action of the novel thiazole derivatives, kinetic analyses were carried out for selected compounds to compare their transformation by <italic toggle="yes">Pf</italic>PanK and <italic toggle="yes">Hs</italic>PanK3. To date, three phylogenetically distinct types of PanK (type I, type II, and type III) have been characterized, distinguished by their differences in structures, catalytic properties, and inhibition profiles (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B56" ref-type="bibr">56</xref>). All PanKs characterized to date have been shown to exist as homodimers (<xref rid="B57" ref-type="bibr">57</xref><xref rid="B58" ref-type="bibr">&#8211;</xref><xref rid="B64" ref-type="bibr">64</xref>), with the exception of those from <italic toggle="yes">P. falciparum</italic> and <italic toggle="yes">Toxoplasma gondii</italic>, another apicomplexan parasite (<xref rid="B65" ref-type="bibr">65</xref>). <italic toggle="yes">P. falciparum</italic> expresses two type II PanKs (<italic toggle="yes">Pf</italic>PanK1 and <italic toggle="yes">Pf</italic>PanK2), which have been shown to form a heteromeric complex (<xref rid="B65" ref-type="bibr">65</xref>). To explore the difference in activity of the compounds against <italic toggle="yes">P. falciparum</italic> and HFF/HepG2 cells, we set out to perform kinetic analysis of <italic toggle="yes">Hs</italic>PanK3, a well-characterized homodimeric type II PanK expressed in humans, in the presence of selected compounds. <italic toggle="yes">Hs</italic>PanK3 was selected in preference to the other human PanKs on the basis that its cytosolic location (<xref rid="B66" ref-type="bibr">66</xref><xref rid="B67" ref-type="bibr">&#8211;</xref><xref rid="B69" ref-type="bibr">69</xref>) and feedback inhibition properties (<xref rid="B62" ref-type="bibr">62</xref>, <xref rid="B69" ref-type="bibr">69</xref><xref rid="B70" ref-type="bibr">&#8211;</xref><xref rid="B71" ref-type="bibr">71</xref>) closely match those of <italic toggle="yes">Pf</italic>PanK (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B65" ref-type="bibr">65</xref>). <italic toggle="yes">Hs</italic>PanK3 protein was expressed in <italic toggle="yes">E. coli</italic> as a His-tagged protein and purified by affinity chromatography (<xref rid="SuF1" ref-type="supplementary-material">Fig. S4</xref>). The purified <italic toggle="yes">Hs</italic>PanK3 protein was biochemically characterized and had a <italic toggle="yes">K</italic><sub>m</sub> for pantothenate of 24 &#177; 4 &#181;M (<italic toggle="yes">n</italic> = 3; mean &#177; SEM; <xref rid="T2" ref-type="table">Table 2</xref> and <xref rid="F5" ref-type="fig">Fig. 5</xref>), which is consistent with previous reports (17 &#177; 1 &#181;M) (<xref rid="B70" ref-type="bibr">70</xref>, <xref rid="B72" ref-type="bibr">72</xref>). All tested compounds were found to be substrates of <italic toggle="yes">Hs</italic>PanK3. Substrate inhibition, which is a common phenomenon in enzyme kinetics (<xref rid="B73" ref-type="bibr">73</xref><xref rid="B74" ref-type="bibr">&#8211;</xref><xref rid="B75" ref-type="bibr">75</xref>), was observed for compounds <bold>2c</bold> and <bold>2e</bold> (<xref rid="F2 F5" ref-type="fig">Fig. 2 and 5</xref>). Such inhibition is typically caused by simultaneous binding of two or more substrate molecules to the enzyme, resulting in the formation of an unproductive enzyme&#8211;substrate complex (<xref rid="B76" ref-type="bibr">76</xref>). This increases with rising substrate concentration. Equation 1 (Y = V<sub>max</sub>*X/(<italic toggle="yes">K</italic><sub>m</sub> + X*(1 + X/<italic toggle="yes">K</italic><sub>i</sub>))), X: substrate concentration, Y: enzyme activity, V<sub>max</sub>: maximum enzyme activity, <italic toggle="yes">K</italic><sub>m</sub>: Michaelis&#8211;Menten constant, and <italic toggle="yes">K</italic><sub>i</sub>: inhibitor constant), which accounts for substrate inhibition, was used to determine the kinetic parameters of <bold>2c</bold> and <bold>2e</bold>, instead of the standard Michaelis&#8211;Menten equation that was used for the other compounds. We found that <italic toggle="yes">Hs</italic>PanK3 exhibited a 1.8-fold to 4.2-fold higher <italic toggle="yes">K</italic><sub>m</sub> (i.e.<italic toggle="yes">,</italic> lower affinity) for all selected compounds compared to that of the natural substrate pantothenate (<italic toggle="yes">P</italic> &#8804;0.003). By contrast, the turnover numbers (<italic toggle="yes">k</italic><sub>cat</sub>) of <italic toggle="yes">Hs</italic>PanK3 for <bold>3f</bold> were slightly higher than that of pantothenate (i.e.<italic toggle="yes">,</italic> higher efficiency, <italic toggle="yes">P</italic> = 0.0059). The <italic toggle="yes">k</italic><sub>cat</sub> for other compounds was the same as (<bold>1a</bold>, <bold>1c</bold>, <bold>2c</bold>, and <bold>2e</bold>) or slightly lower (<bold>1e</bold>, <italic toggle="yes">P</italic> &lt;0.0001) than the <italic toggle="yes">k</italic><sub>cat</sub> for pantothenate. The specificity of <italic toggle="yes">Hs</italic>PanK3 for each compound was then evaluated by computing the <italic toggle="yes">k</italic><sub>cat</sub>/<italic toggle="yes">K</italic><sub>m</sub> values. In the presence of the compounds with sub-micromolar antiplasmodial activity (<bold>1a</bold>, <bold>1e,</bold> or <bold>2e</bold>), <italic toggle="yes">Hs</italic>PanK3 exhibited a 2.5-fold to 4.5-fold lower <italic toggle="yes">k</italic><sub>cat</sub>/<italic toggle="yes">K</italic><sub>m</sub> (i.e., lower specificity) compared to the natural substrate pantothenate (<italic toggle="yes">P</italic> &lt; 0.0001; <xref rid="T2" ref-type="table">Table 2</xref>). Similar results were obtained for <bold>1c</bold>, <bold>2c</bold>, and <bold>3f</bold> (~3-fold lower, <italic toggle="yes">P</italic> &lt; 0.0001), consistent with <italic toggle="yes">Hs</italic>PanK3 having a much higher catalytic efficiency for pantothenate than for the thiazole analogs. Together with the lack of toxicity observed on HFF and HepG2 cells, these data imply that the compounds may not be substantially metabolized &#960;&#960;by the human enzyme.</p><table-wrap position="float" id="T2" orientation="portrait"><label>TABLE 2</label><caption><p>Kinetic data calculated for <italic toggle="yes">Hs</italic>PanK3 in the presence of various pantothenamide-mimics<xref rid="T2_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="center" valign="top" colspan="2" rowspan="1">Compound</th><th align="center" valign="top" colspan="1" rowspan="1"><italic toggle="yes">K</italic><sub>m</sub> (&#181;M)</th><th align="center" valign="top" colspan="1" rowspan="1"><italic toggle="yes">k</italic><sub>cat</sub> (s<sup>&#8722;1</sup>)</th><th align="center" valign="top" colspan="1" rowspan="1"><italic toggle="yes">k</italic><sub>cat</sub> / <italic toggle="yes">K</italic><sub>m</sub><break/>(mM<sup>&#8722;1</sup> s<sup>&#8722;1</sup>)</th><th align="center" valign="top" colspan="1" rowspan="1"><italic toggle="yes">K</italic><sub>i</sub> (&#181;M)<xref rid="T2_FN3" ref-type="table-fn"><sup><italic toggle="yes">c</italic></sup></xref></th></tr></thead><tbody><tr><td align="center" valign="top" colspan="1" rowspan="1">D-Pantothenate</td><td align="left" valign="top" colspan="1" rowspan="1">
<inline-graphic xlink:href="aac.00331-25.inline024.jpg"/>
</td><td align="center" valign="top" colspan="1" rowspan="1">24 &#177; 4</td><td align="center" valign="top" colspan="1" rowspan="1">0.64 &#177; 0.02</td><td align="center" valign="top" colspan="1" rowspan="1">30 &#177; 3</td><td align="center" valign="top" colspan="1" rowspan="1">
<bold>-</bold>
</td></tr><tr><td align="center" valign="top" colspan="1" rowspan="1">1a</td><td align="left" valign="top" colspan="1" rowspan="1">
<inline-graphic xlink:href="aac.00331-25.inline025.jpg"/>
</td><td align="center" valign="top" colspan="1" rowspan="1">100 &#177; 7</td><td align="center" valign="top" colspan="1" rowspan="1">0.64 &#177; 0.01</td><td align="center" valign="top" colspan="1" rowspan="1">6.6 &#177; 0.4</td><td align="center" valign="top" colspan="1" rowspan="1">
<bold>-</bold>
</td></tr><tr><td align="center" valign="top" colspan="1" rowspan="1">1c</td><td align="left" valign="top" colspan="1" rowspan="1">
<inline-graphic xlink:href="aac.00331-25.inline026.jpg"/>
</td><td align="center" valign="top" colspan="1" rowspan="1">65 &#177; 7</td><td align="center" valign="top" colspan="1" rowspan="1">0.61 &#177; 0.02</td><td align="center" valign="top" colspan="1" rowspan="1">10.2 &#177; 0.9</td><td align="center" valign="top" colspan="1" rowspan="1">
<bold>-</bold>
</td></tr><tr><td align="center" valign="top" colspan="1" rowspan="1">1e</td><td align="left" valign="top" colspan="1" rowspan="1">
<inline-graphic xlink:href="aac.00331-25.inline027.jpg"/>
</td><td align="center" valign="top" colspan="1" rowspan="1">42 &#177; 4</td><td align="center" valign="top" colspan="1" rowspan="1">0.399 &#177; 0.005</td><td align="center" valign="top" colspan="1" rowspan="1">10 &#177; 1</td><td align="center" valign="top" colspan="1" rowspan="1">
<bold>-</bold>
</td></tr><tr><td align="center" valign="top" colspan="1" rowspan="1">2c<xref rid="T2_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">
<inline-graphic xlink:href="aac.00331-25.inline028.jpg"/>
</td><td align="center" valign="top" colspan="1" rowspan="1">69 &#177; 6</td><td align="center" valign="top" colspan="1" rowspan="1">0.63 &#177; 0.02</td><td align="center" valign="top" colspan="1" rowspan="1">9.3 &#177; 0.5</td><td align="center" valign="top" colspan="1" rowspan="1">2,654 &#177; 733</td></tr><tr><td align="center" valign="top" colspan="1" rowspan="1">2e<xref rid="T2_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">
<inline-graphic xlink:href="aac.00331-25.inline029.jpg"/>
</td><td align="center" valign="top" colspan="1" rowspan="1">67 &#177; 10</td><td align="center" valign="top" colspan="1" rowspan="1">0.73 &#177; 0.05</td><td align="center" valign="top" colspan="1" rowspan="1">12 &#177; 1</td><td align="center" valign="top" colspan="1" rowspan="1">4,337 &#177; 961</td></tr><tr><td align="center" valign="top" colspan="1" rowspan="1">3f</td><td align="left" valign="top" colspan="1" rowspan="1">
<inline-graphic xlink:href="aac.00331-25.inline030.jpg"/>
</td><td align="center" valign="top" colspan="1" rowspan="1">75 &#177; 11</td><td align="center" valign="top" colspan="1" rowspan="1">0.73 &#177; 0.02</td><td align="center" valign="top" colspan="1" rowspan="1">10.7 &#177; 0.8</td><td align="center" valign="top" colspan="1" rowspan="1">-</td></tr></tbody></table><table-wrap-foot><fn id="T2_FN1"><label>
<sup>
<italic toggle="yes">a</italic>
</sup>
</label><p>Unless otherwise stated, kinetic parameters reported in the table were determined for each experiment by fitting the Michaelis&#8211;Menten equation to the data.</p></fn><fn id="T2_FN2"><label>
<sup>
<italic toggle="yes">b</italic>
</sup>
</label><p>For these compounds, the parameters were determined by fitting the data to equation 1 that accounts for substrate inhibition.</p></fn><fn id="T2_FN3"><label>
<sup>
<italic toggle="yes">c</italic>
</sup>
</label><p><italic toggle="yes">K<sub>i</sub></italic>, the inhibitor constant, was determined for compounds that displayed substrate inhibition, that is, a decrease in <italic toggle="yes">V</italic><sub>max</sub> at higher substrate concentrations. Data were collected from three independent experiments, each performed in triplicate (errors represent SEM).</p></fn></table-wrap-foot></table-wrap><fig position="float" fig-type="figure" id="F5" orientation="portrait"><label>Fig 5</label><caption><p>Examples of kinetics plots for <italic toggle="yes">Hs</italic>PanK3 in the presence of representative compounds. Velocities were determined as a function of pantothenate or compound concentration. The data points were fit to the Michaelis&#8211;Menten nonlinear regression equation to determine kinetic parameters. For <bold>2e</bold>, Equation 1, which accounts for substrate inhibition, was used to fit the data. Data are averaged from nine experiments, carried out on three different days. Error bars represent SEM and are not visible if smaller than the symbols. Kinetics of other compounds are shown in <xref rid="SuF1" ref-type="supplementary-material">Fig. S5</xref>.</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.00331-25.f005.jpg"><alt-text>Four Michaelis-Menten plots compare enzyme velocity versus substrate concentration for D-pantothenate, 1a, 1e, and 2e. D-pantothenate and 1a display classic saturation kinetics; 1e shows reduced Vmax, while 2e suggests substrate inhibition at high levels.</alt-text></graphic></fig><p>Additional experiments were performed with the same selected compounds to further investigate their antiplasmodial mechanism(s) of action. We are specifically interested in determining whether there is a correlation between the antiplasmodial activity of the compounds and their interaction with <italic toggle="yes">Pf</italic>PanK, as we have shown that the thiazole derivatives compete with pantothenate (<xref rid="T1" ref-type="table">Table 1</xref>, <xref rid="SuF1" ref-type="supplementary-material">Fig. S1</xref>). Although we would like to directly interrogate the kinetic parameters of <italic toggle="yes">Pf</italic>PanK in the presence of each compound, the low yields achievable when purifying the enzyme from <italic toggle="yes">P. falciparum</italic> prohibited us from obtaining enough protein for conventional kinetic analysis. As an alternative, we tested the phosphorylation of [<sup>14</sup>C]pantothenate by <italic toggle="yes">Pf</italic>PanK in <italic toggle="yes">P. falciparum</italic> lysates in the presence of each compound at 10&#215; their respective antiplasmodial IC<sub>50</sub> values (<xref rid="T1" ref-type="table">Table 1</xref>, <xref rid="F6" ref-type="fig">Fig. 6A</xref>). Almost complete inhibition (&gt;90%) of pantothenate phosphorylation was observed in the presence of 10&#215; antiplasmodial IC<sub>50</sub> values of <bold>1a</bold>, <bold>1c</bold>, <bold>1e</bold>, <bold>2c</bold>, and <bold>3f</bold>, while approximately 80% inhibition was observed for compound <bold>2e</bold>, which adds another line of evidence that these compounds are competing with pantothenate for direct interaction with <italic toggle="yes">Pf</italic>PanK.</p><fig position="float" fig-type="figure" id="F6" orientation="portrait"><label>Fig 6</label><caption><p>Effect of various compounds on [<sup>14</sup>C]pantothenate phosphorylation by <italic toggle="yes">P. falciparum</italic> lysates. [<sup>14</sup>C]pantothenate and Somogyi reagent were used to detect PanK activity in <italic toggle="yes">P. falciparum</italic> lysates. Compounds were tested at 10&#215; their antiplasmodial IC<sub>50</sub> values in (<bold>A</bold>). The effect of <bold>2e</bold> on [<sup>14</sup>C]pantothenate phosphorylation by <italic toggle="yes">P. falciparum</italic> lysates was tested at various concentrations in (<bold>B</bold>). Data are expressed as a percentage of the pantothenate phosphorylation rate in the DMSO (vehicle) control and are averaged from three independent experiments, each with a different batch of lysate and carried out in triplicate. Error bars represent SEM and are not visible if smaller than the symbols.</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.00331-25.f006.jpg"><alt-text>Bar graph compares phosphorylation rates of tested compounds relative to DMSO control, showing strong inhibition. Dose-response curve indicates compound 2e reduces phosphorylation rate in a concentration-dependent manner with submicromolar efficacy.</alt-text></graphic></fig><p>To examine the interaction of compound <bold>2e</bold>, the most potent antiplasmodial in this series, with <italic toggle="yes">Pf</italic>PanK in more detail, we tested the effect of various concentrations of <bold>2e</bold> on [<sup>14</sup>C]pantothenate phosphorylation. As expected, we observed a reduction in the pantothenate phosphorylation rate by <italic toggle="yes">Pf</italic>PanK (in lysates) as the concentration of <bold>2e</bold> was increased (<xref rid="F6" ref-type="fig">Fig. 6B</xref>). We found that <bold>2e</bold> was equally effective (<italic toggle="yes">P</italic> = 0.256) at inhibiting blood stage parasite proliferation (IC<sub>50</sub> = 0.51 &#177; 0.02 &#181;M; <italic toggle="yes">n</italic> = 3; mean &#177; SEM) and pantothenate phosphorylation (IC<sub>50</sub> = 0.56 &#177; 0.03 &#181;M; <italic toggle="yes">n</italic> = 3; mean &#177; SEM). The IC<sub>50</sub> of <bold>2e</bold> at inhibiting pantothenate phosphorylation is approximately 2.1-fold higher (<italic toggle="yes">P</italic> = 0.046) than the <italic toggle="yes">K</italic><sub>m</sub> for pantothenate that has been reported previously for <italic toggle="yes">Pf</italic>PanK in parasite lysates (270 &#177; 95 nM; mean &#177; SEM) (<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B77" ref-type="bibr">77</xref>, <xref rid="B78" ref-type="bibr">78</xref>). In comparison, <italic toggle="yes">Hs</italic>PanK3 exhibits a 2.8-fold higher <italic toggle="yes">K</italic><sub>m</sub> for <bold>2e</bold> (67 &#177; 10 &#181;M; <italic toggle="yes">n</italic> = 3; mean &#177; SEM); thus, the IC<sub>50</sub> of <bold>2e</bold> at inhibiting <italic toggle="yes">Pf</italic>PanK-mediated pantothenate phosphorylation is 120-fold lower (<italic toggle="yes">P</italic> = 0.0032) than the <italic toggle="yes">K</italic><sub>m</sub> observed for <italic toggle="yes">Hs</italic>PanK3 (<xref rid="T2" ref-type="table">Table 2</xref>), consistent with <bold>2e</bold> interacting with much higher affinity with <italic toggle="yes">Pf</italic>PanK than <italic toggle="yes">Hs</italic>PanK3, and with the absence of toxicity to HFF and HepG2 cells.</p></sec><sec id="s2-4"><title>Computational analysis of pantothenamides</title><p>The mode of action of pantothenamides may involve three bioactivation steps and several CoA-utilizing enzymes; therefore, small structural differences can affect permeability (across both erythrocyte and parasite membranes) as well as their binding to any of the many enzymes that are involved in bioactivation and/or serve as targets. It is therefore challenging to rationalize, for example, the preference for a phenethyl or phenyl group over the linear aliphatic chains observed for series <bold>2</bold> and <bold>3</bold> compounds. Further experiments specifically looking at cell permeability, bioactivation, and target identification might help gain a better understanding of the SARs. As a complementary approach, ligand-based computational studies were used here to gain more insight into SARs. Conformational samplings and electronic charges were calculated using ORCA version 6.0 (<xref rid="B79" ref-type="bibr">79</xref>, <xref rid="B80" ref-type="bibr">80</xref>). The results were visualized in ChimeraX (<xref rid="B81" ref-type="bibr">81</xref><xref rid="B82" ref-type="bibr">&#8211;</xref><xref rid="B83" ref-type="bibr">83</xref>) with SEQCROW (<xref rid="B84" ref-type="bibr">84</xref>, <xref rid="B85" ref-type="bibr">85</xref>). Conformational samplings were obtained from the semi-empirical tight binding (GFN2-xTB) method (<xref rid="B86" ref-type="bibr">86</xref>) and the analytical linearized Poisson&#8211;Boltzmann (ALPB) model (<xref rid="B87" ref-type="bibr">87</xref>) as an implicit solvent model of water. Electronic charge distributions were calculated based on charges from electrostatic potentials using a grid-based method (CHELPG) (<xref rid="B88" ref-type="bibr">88</xref>) at the B3LYP/def2-TZVPPD level of theory.</p><p>We focused on the different thiazole cores and simplified the shared structures of the compounds. Consequently, the pantoyl moiety was reduced to an acetyl group, and the side chain (defined in <xref rid="F1" ref-type="fig">Fig. 1</xref>) was abbreviated with an ethyl or a phenyl substituent. Overall, both the position of the heteroatoms in the ring and the nature of the side chain were found to have a significant impact on the favored conformations and the electronic charges. For series <bold>1</bold> with an ethyl substituent, conformational sampling reveals that a 1,4 N&#183;&#183;&#183;S interaction is key to the stabilization of the amide-thiazole backbone (<xref rid="F7" ref-type="fig">Fig. 7A</xref>). Taking a closer look at the global minimum of the structure, the distance between the nitrogen and sulfur atom is 2.9 &#197;, which is within the sum of the van der Waals radii of 3.35 &#197; (<xref rid="B41" ref-type="bibr">41</xref>). The torsion angle (&#966;SCCN) is &#8722;13.5 degrees, which satisfies the requirement for 1,4 N&#183;&#183;&#183;S interaction (<xref rid="B41" ref-type="bibr">41</xref>). Notably, the lesser negative charge on the amide nitrogen in the ethyl model (&#8722;0.41) than in the phenyl model (&#8722;0.59; <xref rid="F7" ref-type="fig">Figure 7B</xref>) correlates with the proposal that this nitrogen serves as an electron donor in the 1,4 N&#183;&#183;&#183;S interaction. Charge distribution analyses also show that the ring N&#8722;C&#8722;C&#8722;H moiety in series <bold>1</bold> with an ethyl substituent is polarized, similar to that of an amide O&#8722;C&#8722;N&#8722;H moiety. Conversely, a phenyl substituent (rather than ethyl) is detrimental in this series (<xref rid="F7" ref-type="fig">Fig. 7B</xref>). Despite slightly improving the conformational stability of the ensemble (see section 4 of the Supporting Information), installation of a phenyl group not only disrupts the 1,4 N&#183;&#183;&#183;S interaction but also makes the N&#8722;C&#8722;C&#8722;H moiety less polar.</p><fig position="float" fig-type="figure" id="F7" orientation="portrait"><label>Fig 7</label><caption><p>Computational results. Distances and torsion angles are highlighted in teal, and charge distributions are indicated in maroon. The global minimum conformations are shown, except for structure b, which is +0.43 kcal/mol above the global minimum. (<bold>A</bold>) Truncated model structure of series <bold>1</bold> bearing an ethyl substituent. (<bold>B</bold>) Truncated model structure of series <bold>1</bold> bearing a phenyl substituent. (<bold>C</bold>) Truncated model structure of series <bold>2</bold> bearing an ethyl substituent. (<bold>D</bold>) Truncated model structure of series <bold>2</bold> bearing a phenyl substituent. (<bold>E</bold>) Truncated model structure of series <bold>3</bold> bearing an ethyl substituent. (<bold>F</bold>) Truncated model structure of series <bold>3</bold> bearing a phenyl substituent. (<bold>G</bold>) Truncated model structure of N5-Pan bearing an ethyl substituent. (<bold>H</bold>) Truncated model structure of reverse N5-Pan bearing an ethyl substituent. (<bold>I</bold>) Measured torsion angles.</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.00331-25.f007.jpg"><alt-text>Molecular structures display intramolecular hydrogen bonds, partial charges, and distances stabilizing the conformations. Conformational angles differ between compound types, as summarized in the accompanying table with calculated torsional values.</alt-text></graphic></fig><p>As sulfur is positioned away from the amide bond in series <bold>2</bold>, no benefit can be gained from a 1,4 N&#183;&#183;&#183;S interaction (<xref rid="F7" ref-type="fig">Fig. 7C D</xref>). Nevertheless, the different arrangement of the heteroatoms offers new favorable interactions. Unlike series <bold>1</bold>, in series <bold>2,</bold> the introduction of a phenyl substituent (<xref rid="F7" ref-type="fig">Fig. 7D</xref>) significantly stabilizes the conformational ensemble (see section 4 of Supporting Information), consistent with the higher activity of <bold>2e</bold> over that of <bold>2a</bold>. In particular, the thiazole core and the phenyl ring are essentially coplanar across the whole ensemble, implying that they form an important interaction. Previous studies (<xref rid="B89" ref-type="bibr">89</xref><xref rid="B90" ref-type="bibr">&#8211;</xref><xref rid="B91" ref-type="bibr">91</xref>) have suggested that this phenomenon originates from unconventional hydrogen bonds between the heteroatoms and the aromatic C-H bond (C&#8722;H&#183;&#183;&#183;N and C&#8722;H&#183;&#183;&#183;S hydrogen bond). Indeed, the distance between N/S and H calculated here is 2.5 &#197; and 2.6 &#197;, respectively, therefore within the sum of the van der Waals radii (2.75 &#197; and 3.0 &#197;) and confirming this beneficial interaction. A polarized N&#8722;C&#8722;C&#8722;H thiazole backbone is also present in series <bold>2</bold>, indicating its capability of electronically imitating the amide bond of pantothenamides. In addition, the distance between the amide oxygen and thiazole hydrogen is slightly below the sum of the van der Waals radii (2.72 &#197;), suggesting that extra factors may contribute to conformational stability. This may explain, at least in part, the better activity of series <bold>1</bold> and <bold>2</bold> relative to previously reported linear pantothenamides, such as N5-Pan, for which the IC<sub>50</sub> values are 124 &#177; 15 &#181;M and 2.0 &#177; 0.5 &#181;M in the presence and absence of pantetheinases, respectively (<xref rid="B20" ref-type="bibr">20</xref>).</p><p>Results with series <bold>3</bold> compounds somewhat resemble those of series <bold>2</bold>, albeit with less beneficial interactions (<xref rid="F7" ref-type="fig">Fig. 7E and F</xref>), thus paralleling their lower biological activity. The 1,4 N&#183;&#183;&#183;S interaction is absent in series <bold>3</bold>, and the amide oxygen and thiazole hydrogen are too far apart (3.3 &#197; and 3.0 &#197; for the ethyl and phenyl derivatives, respectively) to have any meaningful interactions. Remarkably, charge distribution analysis reveals that no polarized thiazole backbone exists in series <bold>3</bold>, making it electronically unfit to mimic an amide bond. These results correlate well with the fact that series <bold>3</bold> is generally inferior to series <bold>1</bold> and <bold>2</bold> for their antiplasmodial activity. They also tentatively offer a plausible explanation for the different substituent preferences among these series of compounds. For example, the phenyl-thiazole interaction may rationalize the better activity of <bold>3f</bold> over that of <bold>3a</bold> in this series too.</p><p>Although both series <bold>1</bold> and <bold>2</bold> delivered potent antiplasmodial compounds, they had very distinctive SARs. To further explain the difference between the observed SARs, conformational samplings were also computed for the benchmark compounds N5-Pan and reverse N5-Pan. Similar reduction of molecular complexity was applied to facilitate the calculations. The results demonstrate that both compounds exhibit a U-shaped backbone to maximize amide carbonyl&#8211;carbonyl interactions, either through <inline-formula id="ui1"><alternatives><inline-graphic xlink:href="aac.00331-25.im001.jpg"/><mml:math id="u1" display="inline" overflow="scroll"><mml:mi>n</mml:mi><mml:mo>&#8594;</mml:mo><mml:msup><mml:mrow><mml:mi>&#960;</mml:mi></mml:mrow><mml:mrow/></mml:msup></mml:math></alternatives></inline-formula><sup>*</sup> interactions or dipole&#8211;dipole interactions (<xref rid="B92" ref-type="bibr">92</xref><xref rid="B93" ref-type="bibr">&#8211;</xref><xref rid="B94" ref-type="bibr">94</xref>). Analyses of torsion angles were performed to compare amide bonds and the polarized thiazole backbones, where angles of O&#8722;C&#8722;C&#8722;O and H&#8722;N&#8722;N&#8722;H were measured for the two pantothenamides, and angles of O&#8722;C&#8722;C&#8722;N and H&#8722;N&#8722;C&#8722;H were measured in thiazole-containing pantothenamide-mimics. Gratifyingly, the results (<xref rid="F7" ref-type="fig">Fig. 7</xref>) revealed that series <bold>1</bold> bears more resemblance to the normal amide, whereas series <bold>2</bold> with the reverse amide. This correlates well with previous findings that alkyl chains were preferred for compounds with a normal amide, whereas aryl substituents were favored for those with a reverse amide (<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B95" ref-type="bibr">95</xref>).</p></sec></sec><sec sec-type="discussion" id="s3"><title>DISCUSSION</title><p>A goal of this study was to explore the antiplasmodial activity, specificity, and on-target activity of pantothenamide-mimics, which have the labile amide bond replaced with a thiazole to prevent degradation by pantetheinases. We previously had success at replacing this bond with a triazole or an isoxazole (<xref rid="F1" ref-type="fig">Fig. 1C</xref>). Preliminary results (<xref rid="B35" ref-type="bibr">35</xref>) suggested that a sulfur-containing heterocycle could be a promising replacement for the labile amide bond; hence, we were encouraged to synthesize novel thiazole analogs. Three of the 23 compounds displayed sub-micromolar antiplasmodial activity against blood stage-<italic toggle="yes">P. falciparum</italic> in the presence of an extracellular pantothenate concentration of 1 &#181;M, a concentration that is similar to the normal human plasma pantothenate concentration (1.6&#8211;2.7 &#181;M [<xref rid="B96" ref-type="bibr">96</xref>]).</p><p>In the pantothenamide-mimics previously reported by Spry et al<italic toggle="yes">.</italic> (<xref rid="B30" ref-type="bibr">30</xref>), Schalkwijk et al<italic toggle="yes">.</italic> (<xref rid="B29" ref-type="bibr">29</xref>), Guan et al<italic toggle="yes">.</italic> (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B35" ref-type="bibr">35</xref>), and de Vries et al<italic toggle="yes">.</italic> (<xref rid="B36" ref-type="bibr">36</xref>), a two-carbon linker is optimal between the pantoyl and the linear amide mimic, whereas a one-carbon linker was preferred between the pantoyl and the heterocyclic moieties. Therefore, the novel thiazole analogs reported here all harbor a one-carbon linker. The substituent preferences at the ring or amide nitrogen also differ between analogs containing a heterocycle and those with a linear amide. In the case of linear amide mimics, substituents such as phenyl or phenethyl are preferred over linear aliphatic groups (<xref rid="B28" ref-type="bibr">28</xref><xref rid="B29" ref-type="bibr">&#8211;</xref><xref rid="B30" ref-type="bibr">30</xref>). On the other hand, linear aliphatic chains with a length of C4 to C6 are preferred over other alkyl or aryl groups (e.g.<italic toggle="yes">,</italic> 2-methyl-propyl, <italic toggle="yes">p</italic>-trifluoromethylphenyl, phenethyl groups) for molecules containing a triazole or isoxazole (<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B35" ref-type="bibr">35</xref>). By contrast, we found that phenethyl and butyl side chains give equally potent compounds in the thiazole series <bold>1</bold> (see <bold>1a</bold> and <bold>1e</bold>). Surprisingly, in the thiazole series <bold>2</bold> and <bold>3</bold>, the alkyl chains are no longer preferred, and a phenyl group is favored instead (see <bold>2a</bold> and <bold>2e</bold>; <bold>3a</bold> and <bold>3f</bold>), yet substituents on the phenyl ring are detrimental. Preliminary computational studies were used to rationalize these SARs. A ligand-based approach was used, considering the complex mode of action of these molecules and the several steps needed for their localization into the parasite. The results confirm that both the geometry of the heterocycles and the position of heteroatoms have a considerable impact on the side chain preference and thus on their biological activities. This was consistent with previous findings that isosteric heterocycles showed a wide range of activities. The rationale behind the compounds in this study was tentatively explored by the conformational sampling as well as charge analysis of the molecules. Overall, this explains why the biological activity of pantothenamide mimics is so easily tuned, which is highly advantageous in drug development.</p><p>Kinetic analyses with <italic toggle="yes">Hs</italic>PanK3 revealed that the tested thiazole analogs are substrates of the enzyme, yet with lower specificity than pantothenate, as manifested by the higher <italic toggle="yes">K</italic><sub>m</sub> and lower <italic toggle="yes">k</italic><sub>cat</sub>/<italic toggle="yes">K</italic><sub>m</sub> values. For comparison, we employed a [<sup>14</sup>C]pantothenate-based phosphorylation assay to investigate the effect of selected compounds on pantothenate phosphorylation in parasite lysates. This radiolabeled assay is unable to distinguish whether a compound is a substrate or an inhibitor, but it can show whether the compound competes with pantothenate for binding to <italic toggle="yes">Pf</italic>PanK. However, based on the <italic toggle="yes">Hs</italic>PanK3 data presented above and a previous report that demonstrated that a similar triazole derivative (compound <bold>i</bold>, <xref rid="F1" ref-type="fig">Fig. 1C</xref>) is a <italic toggle="yes">Pf</italic>PanK substrate (<xref rid="B21" ref-type="bibr">21</xref>), we hypothesize that the compounds tested here are <italic toggle="yes">Pf</italic>PanK substrates, rather than inhibitors. We show that the most active compound (<bold>2e</bold>) is equally effective at inhibiting the phosphorylation of pantothenate by <italic toggle="yes">Pf</italic>PanK than at preventing the proliferation of intraerythrocytic <italic toggle="yes">P. falciparum</italic> parasites, yet we are not proposing that <italic toggle="yes">Pf</italic>PanK is the target of <bold>2e</bold>, or more generally, the target of this series of compounds. Instead, it is likely that the target is downstream in the CoA biosynthetic pathway and/or a CoA-utilizing enzyme. This is consistent with previous reports on the triazole and reverse amide pantothenamide-mimics (<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B36" ref-type="bibr">36</xref>). The latter were reported to be metabolized into CoA antimetabolites, which target and inhibit acetyl-CoA synthetase (<xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B36" ref-type="bibr">36</xref>). Our data are consistent with the thiazole-containing pantothenamide-mimics sharing a similar mechanism of action as the previously reported ones.</p><p>Remarkably, our results with HFF and HepG2 cells suggest that the compounds may not be cytotoxic to mammalian cells. Considering the fact that the compounds are substrates for <italic toggle="yes">Hs</italic>PanK3, one explanation for the lack of toxicity against HFF and HepG2 cells may be that the compounds are not able to permeate the cells, as previously hypothesized by Howieson et al<italic toggle="yes">.</italic> (<xref rid="B32" ref-type="bibr">32</xref>) for HFF cells. Alternatively, the compounds may be phosphorylated by human PanK but not metabolized further by downstream enzymes of the CoA biosynthetic pathway in HFF/HepG2 cells (and/or may be rapidly hydrolyzed), as opposed to in <italic toggle="yes">P. falciparum</italic>, where their phosphorylated form subsequently rejoins the pathway as substrates of <italic toggle="yes">Pf</italic>PPAT and <italic toggle="yes">Pf</italic>DPCK, generating antiplasmodial CoA antimetabolites (<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B22" ref-type="bibr">22</xref>). If indeed these compounds exert their activity by inhibiting CoA-utilizing enzymes, they would be ineffective in HFF and HepG2 cells due to the lack of production of the CoA antimetabolites. An alternative explanation is that HFF or HepG2 cells do generate the CoA antimetabolites, but they are ineffective at inhibiting downstream CoA-utilizing enzymes. Additional work is required to differentiate between these possibilities.</p><p>We propose that replacing the labile amide group of pantothenamides with a thiazole ring is a promising strategy to identify blood-stable antiplasmodial agents targeting CoA metabolism/utilization. Additional SAR studies, in particular at the side chain of both thiazole series <bold>1</bold> and <bold>2</bold>, and further biological testing are worthy of investigation.</p></sec><sec sec-type="materials|methods" id="s4"><title>MATERIALS AND METHODS</title><sec id="s4-1"><title>Cell culture</title><p>Culturing of intraerythrocytic stage <italic toggle="yes">P. falciparum</italic> parasites (3D7 strain) was carried out using a method adapted from Trager and Jensen (<xref rid="B97" ref-type="bibr">97</xref>) and Allen and Kirk (<xref rid="B98" ref-type="bibr">98</xref>). Parasites were maintained within human, male or female, erythrocytes (typically Group O+, Rh+, 4% hematocrit) in RPMI-1640 medium (Thermo Fisher Scientific, catalogue number 72400120) supplemented with 25 mM HEPES, 11 mM glucose, 200 &#181;M hypoxanthine, 24 &#181;g/mL gentamicin and 6 g/L Albumax II on a horizontally rotating shaking incubator (New Brunswick Innova 42/42R) at 37&#176;C under an atmosphere of 96% nitrogen, 3% carbon dioxide, and 1% oxygen.</p><p>HFF cells were maintained <italic toggle="yes">in vitro</italic> in DMEM supplemented with 10% (vol/vol) newborn calf serum, 50 units/mL penicillin, 50 &#181;g/mL streptomycin, 10 &#181;g/mL gentamicin, 0.2 mM L-glutamine, and 0.25 &#181;g/mL amphotericin B, as previously described (<xref rid="B99" ref-type="bibr">99</xref>). HepG2 cells were maintained in RPMI-1640 medium (Thermo Fisher Scientific, catalogue number 72400120) supplemented with 10% (vol/vol) fetal bovine serum, 50 units/mL penicillin, and 50 &#181;g/mL streptomycin.</p></sec><sec id="s4-2"><title><italic toggle="yes">In vitro</italic> parasite proliferation assay</title><p>To evaluate the effect of each compound on the <italic toggle="yes">in vitro</italic> proliferation of <italic toggle="yes">P. falciparum</italic> parasites, a SYBR Safe-based fluorescence assay was used as previously described (<xref rid="B32" ref-type="bibr">32</xref>). All pantothenamide-mimics tested were initially dissolved to a concentration of 200 mM in DMSO. The final DMSO concentration in the assay never exceeded 0.1% (vol/vol). Assays were performed using the same medium used to culture the parasites. Where specified, 100 &#181;M sodium pantothenate (Yick-Vic Chemicals and Pharmaceuticals, Hong Kong) was added to the medium. Assays were set up with synchronous ring-stage <italic toggle="yes">P. falciparum</italic>-infected erythrocytes in 96-well microtiter plates. Parasites were synchronized using 5% (wt/vol) sorbitol (<xref rid="B100" ref-type="bibr">100</xref>). Two-fold serial dilutions of the compound in complete medium were then added to the wells of each plate in triplicate (total volume of 100 &#181;L per well), after which <italic toggle="yes">P. falciparum</italic>-infected erythrocytes were added to a final volume of 200 &#181;L per well (0.5% parasitemia and 1% hematocrit). <italic toggle="yes">P. falciparum</italic>-infected erythrocytes incubated in the presence of 0.5 &#181;M chloroquine were used as a non-proliferation control, and those incubated in the absence of compounds and chloroquine served as a 100% parasite proliferation control. To minimize &#8220;edge effects&#8221; (<xref rid="B101" ref-type="bibr">101</xref>, <xref rid="B102" ref-type="bibr">102</xref>), the outermost rows and columns of the microtiter plates were not used in the proliferation assays and were filled with 200 &#181;L of medium. The plates were then incubated at 37&#176;C for 96 h under a low-oxygen atmosphere. At the end of the incubation, plates were frozen at &#8722;80&#176;C to lyse the cells. Following thawing, the content of each well was resuspended in the plates by pipetting, and then 100 &#181;L from each well was transferred to a second 96-well microtiter plate containing 100 &#181;L of lysis buffer (20 mM Tris, pH 7.5; 5 mM EDTA; 0.008% [wt/vol] saponin and 0.08% [vol/vol] Triton X-100) with SYBR Safe DNA gel stain (0.2 &#181;L/ml) per well. The cells were gently mixed with the buffer, and the fluorescence signal in each well was then measured using a FLUOstar OPTIMA microplate reader with excitation and emission wavelengths of 490 and 520 nm, respectively, after setting the gain on a 100% parasite proliferation control well. The fluorescence in the non-proliferation control wells was subtracted from the fluorescence readings in the other wells prior to further analysis. Parasite proliferation, calculated as a percentage of the fluorescence measured in the test wells relative to the fluorescence measured in the 100% parasite proliferation control wells, was then plotted against the logarithm of the compound concentration. Using GraphPad Prism, each data set was then fitted with a sigmoidal curve (Y = Bottom + (Top-Bottom)/(1+(IC<sub>50</sub>/X)^HillSlope), where Y represents percentage parasite proliferation, IC<sub>50</sub> represents the concentration of the compound resulting in 50% parasite proliferation, and X represents the compound concentration) using a nonlinear least squares regression. No constraints were used when curve fitting for antiplasmodial assays were performed in the presence of 1 &#181;M pantothenate. The bottom of the curve was constrained to 0 when fitting for antiplasmodial assays were performed in the presence of 100 &#181;M pantothenate. IC<sub>50</sub> values (determined from the sigmoidal curves) were averaged from three independent experiments.</p></sec><sec id="s4-3"><title><italic toggle="yes">In vitro</italic> HFF and HepG2 proliferation assay</title><p><italic toggle="yes">In vitro</italic> HFF proliferation assays were performed as previously described by Howieson et al<italic toggle="yes">.</italic> (<xref rid="B32" ref-type="bibr">32</xref>), with modifications. Confluent HFF cells (in a 75 cm<sup>2</sup> flask) were harvested by treatment with 1 &#215; trypsin&#8211;EDTA (0.25% [wt/vol] trypsin +0.2 g/L EDTA) and diluted in 21 mL of DMEM supplemented with 10% [vol/vol] newborn calf serum (<xref rid="B32" ref-type="bibr">32</xref>). Assays were set up in 96-well microtiter plates in a similar way to that described for the antiplasmodial activity assay. Cycloheximide (10 &#181;M) was used as a non-proliferation control, and 0.1% (vol/vol) DMSO served as a 100% proliferation control. The plates were incubated at 37&#176;C in a CO<sub>2</sub> incubator for 96 h, and the Incucyte Live-Cell Analysis System (Essen BioScience) was used to capture cellular changes and assess cell growth in each well over time. Each well was scanned to capture bright field images, and confluency was assessed at the end of the 96 h incubation, which was then used to evaluate the effect of each compound on the proliferation of HFF cells by comparing it to the 100% proliferation control. The bottom of the curve was constrained to 0 when fitting for HFF proliferation assays using GraphPad Prism.</p><p><italic toggle="yes">In vitro</italic> HepG2 proliferation assays were performed similarly to the HFF proliferation assays with modifications. Confluent HepG2 cells were harvested by treatment with 1 &#215; trypsin&#8211;EDTA and diluted in RPMI-1640 supplemented with 10% (vol/vol) fetal bovine serum. Assays were set up in 96-well microtiter plates with 20,000 cells per well. Puromycin (10 &#181;M) was used as a non-proliferation control, and 0.1% (vol/vol) DMSO served as a 100% proliferation control. The plates were incubated at 37&#176;C in a CO<sub>2</sub> incubator for 72 h, and the Incucyte Live-Cell Analysis System (Essen BioScience) was used to capture cellular changes and assess cell growth in each well over time as described above for the HFF proliferation assays. The bottom of the curve was constrained to 0 when fitting for HepG2 proliferation assays using GraphPad Prism.</p></sec><sec id="s4-4"><title>Preparation of <italic toggle="yes">P. falciparum</italic> lysates</title><p>Parasite lysates were prepared from saponin-isolated mature trophozoite-stage parasites as described by Saliba et al<italic toggle="yes">.</italic> (<xref rid="B14" ref-type="bibr">14</xref>), with modifications. Briefly, a culture with predominantly trophozoite stage parasites was thoroughly mixed with saponin (0.05% [wt/vol] final concentration) and centrifuged at 2,000 &#215; <italic toggle="yes">g</italic> for 8 min at 4&#176;C. The pelleted parasites were then transferred to a 1.5 mL tube and washed three times (16,000 &#215; <italic toggle="yes">g</italic>, 1 min each time) with cold malaria saline (125 mM NaCl, 5 mM KCl, 25 mM HEPES, 20 mM glucose, 1 mM MgCl<sub>2</sub>, pH 7.1). Subsequently, washed saponin-isolated parasites were suspended in 1 mL of 10 mM Tris/Cl, pH 7.4, followed by trituration (10 times) through a SafetyGlide injection needle (25-gauge). The lysates were then centrifuged at 16,000 &#215; <italic toggle="yes">g</italic> for 30 min at 4&#176;C, and the supernatant was transferred to a new tube. The concentration of the lysates was then determined using the Bradford reagent.</p></sec><sec id="s4-5"><title>[<sup>14</sup>C]pantothenate phosphorylation assay</title><p>Phosphorylation of [<sup>14</sup>C]pantothenate was determined using a combination of zinc sulphate (ZnSO<sub>4</sub>) and barium hydroxide (Ba(OH)<sub>2</sub>) (Somogyi reagent) as previously described (<xref rid="B78" ref-type="bibr">78</xref>). In the 125 min time course, each reaction (650 &#181;L) contained a final concentration of 50 mM Tris-Cl (pH 7.4), 5 mM ATP, 5 mM MgCl<sub>2</sub>, 2 &#181;M (0.1 &#181;Ci/mL) [<sup>14</sup>C]pantothenate, and 60 &#181;g of total parasite lysate. The compounds were added at their 10&#215; antiplasmodial IC<sub>50</sub> values or at various concentrations to generate dose&#8211;response curves. Mixtures were incubated at 37&#176;C throughout the experiment, and reactions were initiated by the addition of the lysates. A reaction with identical components to the test reactions but lacking the parasite lysate was prepared to serve as a no-phosphorylation negative control, and a reaction with DMSO vehicle control (0.2% vol/vol) served as a positive control. At pre-determined time points, 50 &#181;L of the reaction mixture was transferred in triplicate to wells of a 96-well filter plate with 0.2 &#181;m hydrophilic polyvinylidene fluoride (PVDF) membrane filter (Corning), which had been pre-loaded with 50 &#181;L of 150 mM Ba(OH)<sub>2</sub>. The reaction mixtures were thoroughly mixed with the Ba(OH)<sub>2</sub> in the wells to precipitate the enzyme and terminate the phosphorylation reaction. After all reactions had been terminated, phosphorylated compounds in each well were precipitated by the addition of 50 &#181;L of 150 mM ZnSO<sub>4</sub> to generate the Somogyi reagent. The plate was then washed twice with deionized H<sub>2</sub>O and once with 95% (vol/vol) ethanol using a vacuum manifold to remove the non-phosphorylated [<sup>14</sup>C]pantothenate and was subsequently dried overnight at 37&#176;C in a non-humidified incubator. The following day, 30 &#181;L of Microscint-O (PerkinElmer) was added to each well, and the plate was sealed on the top and bottom with TopSeal-A Plus sealing film (PerkinElmer). A Packard Microplate Scintillation and Luminescence Counter was used to measure the radioactivity in each well immediately after the plate had been sealed. To determine the total radioactivity in each phosphorylation assay, 50 &#181;L of each reaction mixture was added to the wells of an OptiPlate-96 microplate (PerkinElmer) in triplicate and was then thoroughly mixed with 150 &#181;L of Microscint-40 (PerkinElmer), and the radioactivity was measured in the same manner. Phosphorylation of [<sup>14</sup>C]pantothenate, calculated as a percentage of the radioactivity measured in the test wells relative to the total radioactivity in the phosphorylation assay, was then plotted against the reaction time. Each data set was analyzed by linear regression, from which the phosphorylation rate of each reaction was then determined and expressed as a percentage of the phosphorylation rate of the DMSO-positive control reaction.</p></sec><sec id="s4-6"><title><italic toggle="yes">Hs</italic>PanK protein cloning, expression, and purification</title><p>The gene encoding the catalytic core domain of human PanK3 (amino acid residues 12&#8211;368) was synthesized and cloned into the pET28a(+) expression vector using the NdeI and BamHI restriction sites to produce an N-terminal His6-tagged protein (Bio Basic Inc.). The plasmid was transformed into <italic toggle="yes">E. coli</italic> BL21(DE3) cells, which were cultured in Terrific Broth (TB) medium containing 50 &#181;g/mL kanamycin at 37&#176;C. When the culture reached an optical density at 600 nm (OD<sub>600</sub>) of 0.6, protein expression was induced by adding 1.0 mM isopropyl &#946;-D-thiogalactoside (IPTG), followed by incubation at 18&#176;C for 17&#8211;18 h. The cells were then harvested and resuspended in lysis buffer (20 mM Tris-HCl, pH 7.5, 500 mM NaCl, 5 mM imidazole, 5% [vol/vol] glycerol) supplemented with 1 mM PMSF (phenylmethylsulfonyl fluoride) and lysozyme (5 mg/g of the cell pellet). The suspension was then sonicated on ice, and the resulting lysate was centrifuged twice at 54,000 &#215; <italic toggle="yes">g</italic> for 30 min at 4&#176;C.</p><p>The clarified supernatant was incubated with Ni-NTA resin (Cytiva) pre-equilibrated with lysis buffer containing 5 mM imidazole at 4&#176;C. After binding, the resin was washed with lysis buffer containing 30 mM imidazole, then eluted with lysis buffer containing 250 mM imidazole. The eluted <italic toggle="yes">Hs</italic>PanK3 protein was dialyzed against storage buffer (20 mM Tris-HCl, pH 7.5, 200 mM NaCl, 5% [vol/vol] glycerol) and concentrated. The purified protein was stored at &#8722;80&#176;C. Protein purity was assessed using SDS-PAGE and deemed &gt;50% (<xref rid="SuF1" ref-type="supplementary-material">Fig. S4</xref>).</p></sec><sec id="s4-7"><title><italic toggle="yes">Hs</italic>PanK kinetic assays</title><p>The enzyme assay was adapted from a previously described method (<xref rid="B103" ref-type="bibr">103</xref>), which links the production of ADP to the consumption of NADH through the enzymatic activities of pyruvate kinase and lactic dehydrogenase. Reactions were conducted in 96-well microtiter plates, and the decrease in NADH concentration was measured at 340 nm at 30 s intervals after incubation at 30&#176;C. Each reaction mixture (200 &#181;L) contained the desired compound (substrate) at variable concentrations (0&#8211;2,000 &#181;M), ATP (1.5 mM), NADH (0.3 mM), phospho(enol)pyruvate (2.0 mM), MgCl<sub>2</sub> (10 mM), KCl (20 mM), a commercial pyruvate kinase/lactic dehydrogenase mixture (12 units, Sigma-Aldrich), and pantothenate kinase (0.48 &#181;M) in 50 mM Tris&#8211;HCl buffer (pH 7.6). The reaction was initiated with the addition of ATP. The kinetic parameters were determined by fitting the rate data into the Michaelis&#8211;Menten equation using GraphPad Prism 8.0 with nonlinear regressions. Data were collected from three independent experiments, each performed in triplicate to verify the trends and optimize the selected concentrations. The kinetic parameters were calculated from the most complete triplicate set of data, and errors represent SEM. For cases where substrate inhibition was suspected, the same conditions were used, but the data were fitted using the built-in Equation 1 (Y = V<sub>max</sub>*X/(<italic toggle="yes">K</italic><sub>m</sub> +X*(1 + X/<italic toggle="yes">K</italic><sub>i</sub>)) from GraphPad Prism, where X and Y represent substrate concentration and enzyme activity, respectively, V<sub>max</sub> is the maximum enzyme activity in the same units as Y, and the <italic toggle="yes">K</italic><sub>m</sub> and <italic toggle="yes">K</italic><sub>i</sub> are the Michaelis&#8211;Menten and the inhibitor constants, respectively, both in the same units as X. Equation 1 is based on Equation 5.44, in RA Copeland, Enzymes, 2nd edition, Wiley, 2000.</p></sec><sec id="s4-8"><title>Compound synthesis and characterization</title><p>Details of chemical synthesis as well as compound characterization are shown in Supporting Information 2. NMR spectra are also included starting on page S40.</p></sec><sec id="s4-9"><title>Statistics</title><p>Statistical analysis was carried out using unpaired, two-tailed Student&#8217;s t-test using GraphPad Prism 10.0.</p></sec></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>We are grateful to the Canberra Branch of the Australian Red Cross Lifeblood for the provision of red blood cells and to members of the van Dooren Lab, Australian National University, for maintaining the HFF cultures. We also thank Compute Canada for providing a platform for computational studies, Dr. Kirill Levin for help with NMR at McGill, and Dr. Alexander S. Wahba and Mr. Nadim K. Saadeh for HRMS analyses at McGill. Free academic use of ORCA and ChimeraX is greatly appreciated.</p><p>This work was supported by the Canadian Institute of Health Research (CIHR; grant PJT186220 to K.A. and K.J.S.).</p><p>All parasite, <italic toggle="yes">Pf</italic>PanK, HFF, and HepG2 experiments were performed by X.L. Chemical compounds were synthesized by A.W.C., A.P., and C.B.L. <italic toggle="yes">Hs</italic>PanK3 was produced and assayed by M.N. Computational studies were performed by C.B.L. The manuscript was written by X.L. and C.B.L. and edited by A.C., M.N., A.P., K.A., and K.J.S. The project was overseen by K.A. and K.J.S.</p></ack><sec sec-type="supplementary-material" id="s5-1"><title>SUPPLEMENTAL MATERIAL</title><p specific-use="print-only">The following material is available online at <ext-link xlink:href="https://doi.org/10.1128/aac.00331-25" ext-link-type="uri">https://doi.org/10.1128/aac.00331-25</ext-link>.</p><supplementary-material id="SuF1" position="float" content-type="local-data" orientation="portrait"><object-id pub-id-type="doi">10.1128/aac.00331-25.SuF1</object-id><label>Supplemental figures</label><caption><title>aac.00331-25-s0001.pdf</title><p>Fig. S1 to S5.</p></caption><media xlink:href="aac.00331-25-s0001.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="SuF2" position="float" content-type="local-data" orientation="portrait"><object-id pub-id-type="doi">10.1128/aac.00331-25.SuF2</object-id><label>Supplemental material</label><caption><title>aac.00331-25-s0002.pdf</title><p>Additional chemistry methodology and data.</p></caption><media xlink:href="aac.00331-25-s0002.pdf" position="float" orientation="portrait"/></supplementary-material><p specific-use="online-only">ASM does not own the copyrights to Supplemental Material that may be linked to, or accessed through, an article. The authors have granted ASM a non-exclusive, world-wide license to publish the Supplemental Material files. Please contact the corresponding author directly for reuse. </p></sec><ref-list><title>REFERENCES</title><ref id="B1"><label>1</label><mixed-citation publication-type="book"><article-title>World Malaria Report</article-title>. <year>2024</year>. <publisher-loc>Geneva</publisher-loc><publisher-name>World Health Organization</publisher-name>. <ext-link xlink:href="https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2024" ext-link-type="uri">https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2024</ext-link>.</mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ashley</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Pyae Phyo</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Woodrow</surname><given-names>CJ</given-names></string-name></person-group>. <year>2018</year>. <article-title>Malaria</article-title>. <source>Lancet</source><volume>391</volume>:<fpage>1608</fpage>&#8211;<lpage>1621</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(18)30324-6</pub-id><pub-id pub-id-type="pmid">29631781</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sutherland</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Tanomsing</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Nolder</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Oguike</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Jennison</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Pukrittayakamee</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Dolecek</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hien</surname><given-names>TT</given-names></string-name>, <string-name name-style="western"><surname>do Ros&#225;rio</surname><given-names>VE</given-names></string-name>, <string-name name-style="western"><surname>Arez</surname><given-names>AP</given-names></string-name>, <etal>et al.</etal></person-group>. <year>2010</year>. <article-title>Two nonrecombining sympatric forms of the human malaria parasite Plasmodium ovale occur globally</article-title>. <source>J Infect Dis</source><volume>201</volume>:<fpage>1544</fpage>&#8211;<lpage>1550</lpage>. doi:<pub-id pub-id-type="doi">10.1086/652240</pub-id><pub-id pub-id-type="pmid">20380562</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Flannery</surname><given-names>EL</given-names></string-name>, <string-name name-style="western"><surname>Chatterjee</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Winzeler</surname><given-names>EA</given-names></string-name></person-group>. <year>2017</year>. <article-title>Antimalarial drug discovery - approaches and progress towards new medicines</article-title>. <source>Nat Rev Microbiol</source><volume>15</volume>:<elocation-id>572</elocation-id>. doi:<pub-id pub-id-type="doi">10.1038/nrmicro.2017.88</pub-id><pub-id pub-id-type="pmid">28736448</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dondorp</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Nosten</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Yi</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Das</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Phyo</surname><given-names>AP</given-names></string-name>, <string-name name-style="western"><surname>Tarning</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lwin</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Ariey</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Hanpithakpong</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Ringwald</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Silamut</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Imwong</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Chotivanich</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Lim</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Herdman</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>An</surname><given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Yeung</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Singhasivanon</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Day</surname><given-names>NPJ</given-names></string-name>, <string-name name-style="western"><surname>Lindegardh</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Socheat</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>White</surname><given-names>NJ</given-names></string-name></person-group>. <year>2009</year>. <article-title>Artemisinin resistance in Plasmodium falciparum malaria</article-title>. <source>N Engl J Med</source><volume>361</volume>:<fpage>455</fpage>&#8211;<lpage>467</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa0808859</pub-id><pub-id pub-id-type="pmid">19641202</pub-id><pub-id pub-id-type="pmcid">PMC3495232</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fairhurst</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Dondorp</surname><given-names>AM</given-names></string-name></person-group>. <year>2016</year>. <article-title>Artemisinin-resistant Plasmodium falciparum malaria</article-title>. <source>Microbiol Spectr</source><volume>4</volume>. doi:<pub-id pub-id-type="doi">10.1128/microbiolspec.EI10-0013-2016</pub-id><pub-id pub-id-type="pmcid">PMC4992992</pub-id><pub-id pub-id-type="pmid">27337450</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Henrici</surname><given-names>RC</given-names></string-name>, <string-name name-style="western"><surname>Namazzi</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Lima-Cooper</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Kato</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Aliwuya</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Dombrowski</surname><given-names>JG</given-names></string-name>, <string-name name-style="western"><surname>Pratt</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Campino</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Conroy</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Sutherland</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>John</surname><given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>Opoka</surname><given-names>RO</given-names></string-name></person-group>. <year>2025</year>. <article-title>Artemisinin partial resistance in Ugandan children with complicated malaria</article-title>. <source>JAMA</source><volume>333</volume>:<fpage>83</fpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2024.22343</pub-id><pub-id pub-id-type="pmid">39540797</pub-id><pub-id pub-id-type="pmcid">PMC11565293</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Burrows</surname><given-names>JN</given-names></string-name>, <string-name name-style="western"><surname>Duparc</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gutteridge</surname><given-names>WE</given-names></string-name>, <string-name name-style="western"><surname>van Huijsduijnen</surname><given-names>RH</given-names></string-name>, <string-name name-style="western"><surname>Kaszubska</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Macintyre</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Mazzuri</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>M&#246;hrle</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Wells</surname><given-names>TNC</given-names></string-name></person-group>. <year>2017</year>. <article-title>Erratum to: new developments in anti-malarial target candidate and product profiles</article-title>. <source>Malar J</source><volume>16</volume>:<elocation-id>151</elocation-id>. doi:<pub-id pub-id-type="doi">10.1186/s12936-017-1809-9</pub-id><pub-id pub-id-type="pmid">28420400</pub-id><pub-id pub-id-type="pmcid">PMC5395931</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wells</surname><given-names>TNC</given-names></string-name>, <string-name name-style="western"><surname>Hooft van Huijsduijnen</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Van Voorhis</surname><given-names>WC</given-names></string-name></person-group>. <year>2015</year>. <article-title>Malaria medicines: a glass half full?</article-title><source>Nat Rev Drug Discov</source><volume>14</volume>:<fpage>424</fpage>&#8211;<lpage>442</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrd4573</pub-id><pub-id pub-id-type="pmid">26000721</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Leonardi</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>YM</given-names></string-name>, <string-name name-style="western"><surname>Rock</surname><given-names>CO</given-names></string-name>, <string-name name-style="western"><surname>Jackowski</surname><given-names>S</given-names></string-name></person-group>. <year>2005</year>. <article-title>Coenzyme A: back in action</article-title>. <source>Prog Lipid Res</source><volume>44</volume>:<fpage>125</fpage>&#8211;<lpage>153</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.plipres.2005.04.001</pub-id><pub-id pub-id-type="pmid">15893380</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Strauss</surname><given-names>E</given-names></string-name></person-group>. <year>2010</year>. <part-title>Coenzyme A Biosynthesis and Enzymology</part-title>, <comment>p</comment><fpage>315</fpage>&#8211;<lpage>410</lpage>. In <person-group person-group-type="editor"><string-name name-style="western"><surname>Mander</surname><given-names>L</given-names></string-name></person-group> (ed), <source>Comprehensive natural products II - Chemistry and biology</source>. <publisher-name>Elsevier</publisher-name>.</mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lehane</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Marchetti</surname><given-names>RV</given-names></string-name>, <string-name name-style="western"><surname>Spry</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>van Schalkwyk</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Teng</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Kirk</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Saliba</surname><given-names>KJ</given-names></string-name></person-group>. <year>2007</year>. <article-title>Feedback inhibition of pantothenate kinase regulates pantothenol uptake by the malaria parasite</article-title>. <source>J Biol Chem</source><volume>282</volume>:<fpage>25395</fpage>&#8211;<lpage>25405</lpage>. doi:<pub-id pub-id-type="doi">10.1074/jbc.M704610200</pub-id><pub-id pub-id-type="pmid">17581817</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Saliba</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Ferru</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Kirk</surname><given-names>K</given-names></string-name></person-group>. <year>2005</year>. <article-title>Provitamin B5 (pantothenol) inhibits growth of the intraerythrocytic malaria parasite</article-title>. <source>Antimicrob Agents Chemother</source><volume>49</volume>:<fpage>632</fpage>&#8211;<lpage>637</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.49.2.632-637.2005</pub-id><pub-id pub-id-type="pmid">15673744</pub-id><pub-id pub-id-type="pmcid">PMC547364</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Saliba</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Horner</surname><given-names>HA</given-names></string-name>, <string-name name-style="western"><surname>Kirk</surname><given-names>K</given-names></string-name></person-group>. <year>1998</year>. <article-title>Transport and metabolism of the essential vitamin pantothenic acid in human erythrocytes infected with the malaria parasite Plasmodium falciparum</article-title>. <source>J Biol Chem</source><volume>273</volume>:<fpage>10190</fpage>&#8211;<lpage>10195</lpage>. doi:<pub-id pub-id-type="doi">10.1074/jbc.273.17.10190</pub-id><pub-id pub-id-type="pmid">9553068</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Spry</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Saliba</surname><given-names>KJ</given-names></string-name></person-group>. <year>2009</year>. <article-title>The human malaria parasite Plasmodium falciparum is not dependent on host coenzyme A biosynthesis</article-title>. <source>J Biol Chem</source><volume>284</volume>:<fpage>24904</fpage>&#8211;<lpage>24913</lpage>. doi:<pub-id pub-id-type="doi">10.1074/jbc.M109.025312</pub-id><pub-id pub-id-type="pmid">19584050</pub-id><pub-id pub-id-type="pmcid">PMC2757193</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Spry</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>van Schalkwyk</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Strauss</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Saliba</surname><given-names>KJ</given-names></string-name></person-group>. <year>2010</year>. <article-title>Pantothenate utilization by Plasmodium as a target for antimalarial chemotherapy</article-title>. <source>Infect Disord Drug Targets</source><volume>10</volume>:<fpage>200</fpage>&#8211;<lpage>216</lpage>. doi:<pub-id pub-id-type="doi">10.2174/187152610791163390</pub-id><pub-id pub-id-type="pmid">20334619</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Spry</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Kirk</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Saliba</surname><given-names>KJ</given-names></string-name></person-group>. <year>2008</year>. <article-title>Coenzyme A biosynthesis: an antimicrobial drug target</article-title>. <source>FEMS Microbiol Rev</source><volume>32</volume>:<fpage>56</fpage>&#8211;<lpage>106</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1574-6976.2007.00093.x</pub-id><pub-id pub-id-type="pmid">18173393</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Clifton</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Bryant</surname><given-names>SR</given-names></string-name>, <string-name name-style="western"><surname>Skinner</surname><given-names>CG</given-names></string-name></person-group>. <year>1970</year>. <article-title>N1-(substituted) pantothenamides, antimetabolites of pantothenic acid</article-title>. <source>Arch Biochem Biophys</source><volume>137</volume>:<fpage>523</fpage>&#8211;<lpage>528</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0003-9861(70)90470-4</pub-id><pub-id pub-id-type="pmid">4909169</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Moolman</surname><given-names>WJA</given-names></string-name>, <string-name name-style="western"><surname>de Villiers</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Strauss</surname><given-names>E</given-names></string-name></person-group>. <year>2014</year>. <article-title>Recent advances in targeting coenzyme A biosynthesis and utilization for antimicrobial drug development</article-title>. <source>Biochem Soc Trans</source><volume>42</volume>:<fpage>1080</fpage>&#8211;<lpage>1086</lpage>. doi:<pub-id pub-id-type="doi">10.1042/BST20140131</pub-id><pub-id pub-id-type="pmid">25110006</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Spry</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Macuamule</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Virga</surname><given-names>KG</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>RE</given-names></string-name>, <string-name name-style="western"><surname>Strauss</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Saliba</surname><given-names>KJ</given-names></string-name></person-group>. <year>2013</year>. <article-title>Pantothenamides are potent, on-target inhibitors of Plasmodium falciparum growth when serum pantetheinase is inactivated</article-title>. <source>PLoS One</source><volume>8</volume>:<elocation-id>e54974</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0054974</pub-id><pub-id pub-id-type="pmid">23405100</pub-id><pub-id pub-id-type="pmcid">PMC3566143</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tjhin</surname><given-names>ET</given-names></string-name>, <string-name name-style="western"><surname>Spry</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Sewell</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Hoegl</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Barnard</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Sexton</surname><given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>Siddiqui</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Howieson</surname><given-names>VM</given-names></string-name>, <string-name name-style="western"><surname>Maier</surname><given-names>AG</given-names></string-name>, <string-name name-style="western"><surname>Creek</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Strauss</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Marquez</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Auclair</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Saliba</surname><given-names>KJ</given-names></string-name></person-group>. <year>2018</year>. <article-title>Mutations in the pantothenate kinase of Plasmodium falciparum confer diverse sensitivity profiles to antiplasmodial pantothenate analogues</article-title>. <source>PLoS Pathog</source><volume>14</volume>:<elocation-id>e1006918</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.ppat.1006918</pub-id><pub-id pub-id-type="pmid">29614109</pub-id><pub-id pub-id-type="pmcid">PMC5882169</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>de Villiers</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Spry</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Macuamule</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Barnard</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wells</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Saliba</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Strauss</surname><given-names>E</given-names></string-name></person-group>. <year>2017</year>. <article-title>Antiplasmodial mode of action of pantothenamides: pantothenate kinase serves as a metabolic activator not as a target</article-title>. <source>ACS Infect Dis</source><volume>3</volume>:<fpage>527</fpage>&#8211;<lpage>541</lpage>. doi:<pub-id pub-id-type="doi">10.1021/acsinfecdis.7b00024</pub-id><pub-id pub-id-type="pmid">28437604</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jansen</surname><given-names>PAM</given-names></string-name>, <string-name name-style="western"><surname>Hermkens</surname><given-names>PHH</given-names></string-name>, <string-name name-style="western"><surname>Zeeuwen</surname><given-names>PLJM</given-names></string-name>, <string-name name-style="western"><surname>Botman</surname><given-names>PNM</given-names></string-name>, <string-name name-style="western"><surname>Blaauw</surname><given-names>RH</given-names></string-name>, <string-name name-style="western"><surname>Burghout</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>van Galen</surname><given-names>PM</given-names></string-name>, <string-name name-style="western"><surname>Mouton</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Rutjes</surname><given-names>FPJT</given-names></string-name>, <string-name name-style="western"><surname>Schalkwijk</surname><given-names>J</given-names></string-name></person-group>. <year>2013</year>. <article-title>Combination of pantothenamides with vanin inhibitors as a novel antibiotic strategy against gram-positive bacteria</article-title>. <source>Antimicrob Agents Chemother</source><volume>57</volume>:<fpage>4794</fpage>&#8211;<lpage>4800</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.00603-13</pub-id><pub-id pub-id-type="pmid">23877685</pub-id><pub-id pub-id-type="pmcid">PMC3811400</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Akinnusi</surname><given-names>TO</given-names></string-name>, <string-name name-style="western"><surname>Vong</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Auclair</surname><given-names>K</given-names></string-name></person-group>. <year>2011</year>. <article-title>Geminal dialkyl derivatives of N-substituted pantothenamides: synthesis and antibacterial activity</article-title>. <source>Bioorg Med Chem</source><volume>19</volume>:<fpage>2696</fpage>&#8211;<lpage>2706</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bmc.2011.02.053</pub-id><pub-id pub-id-type="pmid">21440446</pub-id><pub-id pub-id-type="pmcid">PMC3084188</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hoegl</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Darabi</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Tran</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Awuah</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Kerdo</surname><given-names>ESC</given-names></string-name>, <string-name name-style="western"><surname>Habib</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Saliba</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Auclair</surname><given-names>K</given-names></string-name></person-group>. <year>2014</year>. <article-title>Stereochemical modification of geminal dialkyl substituents on pantothenamides alters antimicrobial activity</article-title>. <source>Bioorg Med Chem Lett</source><volume>24</volume>:<fpage>3274</fpage>&#8211;<lpage>3277</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bmcl.2014.06.013</pub-id><pub-id pub-id-type="pmid">24986662</pub-id><pub-id pub-id-type="pmcid">PMC5226837</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Guan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hachey</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Puri</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Howieson</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Saliba</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Auclair</surname><given-names>K</given-names></string-name></person-group>. <year>2016</year>. <article-title>A cross-metathesis approach to novel pantothenamide derivatives</article-title>. <source>Beilstein J Org Chem</source><volume>12</volume>:<fpage>963</fpage>&#8211;<lpage>968</lpage>. doi:<pub-id pub-id-type="doi">10.3762/bjoc.12.95</pub-id><pub-id pub-id-type="pmid">27340487</pub-id><pub-id pub-id-type="pmcid">PMC4902030</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Barnard</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Mostert</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>van Otterlo</surname><given-names>WAL</given-names></string-name>, <string-name name-style="western"><surname>Strauss</surname><given-names>E</given-names></string-name></person-group>. <year>2018</year>. <article-title>Developing pantetheinase-resistant pantothenamide antibacterials: structural modification impacts on PanK interaction and mode of action</article-title>. <source>ACS Infect Dis</source><volume>4</volume>:<fpage>736</fpage>&#8211;<lpage>743</lpage>. doi:<pub-id pub-id-type="doi">10.1021/acsinfecdis.7b00240</pub-id><pub-id pub-id-type="pmid">29332383</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>de Villiers</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Macuamule</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Spry</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hyun</surname><given-names>Y-M</given-names></string-name>, <string-name name-style="western"><surname>Strauss</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Saliba</surname><given-names>KJ</given-names></string-name></person-group>. <year>2013</year>. <article-title>Structural modification of pantothenamides counteracts degradation by pantetheinase and improves antiplasmodial activity</article-title>. <source>ACS Med Chem Lett</source><volume>4</volume>:<fpage>784</fpage>&#8211;<lpage>789</lpage>. doi:<pub-id pub-id-type="doi">10.1021/ml400180d</pub-id><pub-id pub-id-type="pmid">24900746</pub-id><pub-id pub-id-type="pmcid">PMC4027574</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schalkwijk</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Allman</surname><given-names>EL</given-names></string-name>, <string-name name-style="western"><surname>Jansen</surname><given-names>PAM</given-names></string-name>, <string-name name-style="western"><surname>de Vries</surname><given-names>LE</given-names></string-name>, <string-name name-style="western"><surname>Verhoef</surname><given-names>JMJ</given-names></string-name>, <string-name name-style="western"><surname>Jackowski</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Botman</surname><given-names>PNM</given-names></string-name>, <string-name name-style="western"><surname>Beuckens-Schortinghuis</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Koolen</surname><given-names>KMJ</given-names></string-name>, <string-name name-style="western"><surname>Bolscher</surname><given-names>JM</given-names></string-name>, <etal>et al.</etal></person-group>. <year>2019</year>. <article-title>Antimalarial pantothenamide metabolites target acetyl-coenzyme A biosynthesis in Plasmodium falciparum</article-title>. <source>Sci Transl Med</source><volume>11</volume>:<elocation-id>eaas9917</elocation-id>. doi:<pub-id pub-id-type="doi">10.1126/scitranslmed.aas9917</pub-id><pub-id pub-id-type="pmid">31534021</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Spry</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Barnard</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Kok</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Powell</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Mahesh</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Tjhin</surname><given-names>ET</given-names></string-name>, <string-name name-style="western"><surname>Saliba</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Strauss</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>de Villiers</surname><given-names>M</given-names></string-name></person-group>. <year>2020</year>. <article-title>Toward a stable and potent coenzyme A-targeting antiplasmodial agent: structure-activity relationship studies of N-Phenethyl-&#945;-methyl-pantothenamide</article-title>. <source>ACS Infect Dis</source><volume>6</volume>:<fpage>1844</fpage>&#8211;<lpage>1854</lpage>. doi:<pub-id pub-id-type="doi">10.1021/acsinfecdis.0c00075</pub-id><pub-id pub-id-type="pmid">32375471</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pett</surname><given-names>HE</given-names></string-name>, <string-name name-style="western"><surname>Jansen</surname><given-names>PAM</given-names></string-name>, <string-name name-style="western"><surname>Hermkens</surname><given-names>PHH</given-names></string-name>, <string-name name-style="western"><surname>Botman</surname><given-names>PNM</given-names></string-name>, <string-name name-style="western"><surname>Beuckens-Schortinghuis</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Blaauw</surname><given-names>RH</given-names></string-name>, <string-name name-style="western"><surname>Graumans</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>van de Vegte-Bolmer</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Koolen</surname><given-names>KMJ</given-names></string-name>, <string-name name-style="western"><surname>Rutjes</surname><given-names>FPJT</given-names></string-name>, <string-name name-style="western"><surname>Dechering</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Sauerwein</surname><given-names>RW</given-names></string-name>, <string-name name-style="western"><surname>Schalkwijk</surname><given-names>J</given-names></string-name></person-group>. <year>2015</year>. <article-title>Novel pantothenate derivatives for anti-malarial chemotherapy</article-title>. <source>Malar J</source><volume>14</volume>:<elocation-id>169</elocation-id>. doi:<pub-id pub-id-type="doi">10.1186/s12936-015-0673-8</pub-id><pub-id pub-id-type="pmid">25927675</pub-id><pub-id pub-id-type="pmcid">PMC4425855</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Howieson</surname><given-names>VM</given-names></string-name>, <string-name name-style="western"><surname>Tran</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Hoegl</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Fam</surname><given-names>HL</given-names></string-name>, <string-name name-style="western"><surname>Fu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sivonen</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>XX</given-names></string-name>, <string-name name-style="western"><surname>Auclair</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Saliba</surname><given-names>KJ</given-names></string-name></person-group>. <year>2016</year>. <article-title>Triazole substitution of a labile amide bond stabilizes pantothenamides and improves their antiplasmodial potency</article-title>. <source>Antimicrob Agents Chemother</source><volume>60</volume>:<fpage>7146</fpage>&#8211;<lpage>7152</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.01436-16</pub-id><pub-id pub-id-type="pmid">27645235</pub-id><pub-id pub-id-type="pmcid">PMC5118993</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Guan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Tjhin</surname><given-names>ET</given-names></string-name>, <string-name name-style="western"><surname>Howieson</surname><given-names>VM</given-names></string-name>, <string-name name-style="western"><surname>Kittikool</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Spry</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Saliba</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Auclair</surname><given-names>K</given-names></string-name></person-group>. <year>2018</year>. <article-title>Structure-activity relationships of antiplasmodial pantothenamide analogues reveal a new way by which triazoles mimic amide bonds</article-title>. <source>ChemMedChem</source><volume>13</volume>:<fpage>2677</fpage>&#8211;<lpage>2683</lpage>. doi:<pub-id pub-id-type="doi">10.1002/cmdc.201800327</pub-id><pub-id pub-id-type="pmid">30370998</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jansen</surname><given-names>PAM</given-names></string-name>, <string-name name-style="western"><surname>van der Krieken</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Botman</surname><given-names>PNM</given-names></string-name>, <string-name name-style="western"><surname>Blaauw</surname><given-names>RH</given-names></string-name>, <string-name name-style="western"><surname>Cavina</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Raaijmakers</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>de Heuvel</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Sandrock</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Pennings</surname><given-names>LJ</given-names></string-name>, <string-name name-style="western"><surname>Hermkens</surname><given-names>PHH</given-names></string-name>, <string-name name-style="western"><surname>Zeeuwen</surname><given-names>PLJM</given-names></string-name>, <string-name name-style="western"><surname>Rutjes</surname><given-names>FPJT</given-names></string-name>, <string-name name-style="western"><surname>Schalkwijk</surname><given-names>J</given-names></string-name></person-group>. <year>2019</year>. <article-title>Stable pantothenamide bioisosteres: novel antibiotics for Gram-positive bacteria</article-title>. <source>J Antibiot (Tokyo)</source><volume>72</volume>:<fpage>682</fpage>&#8211;<lpage>692</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41429-019-0196-6</pub-id><pub-id pub-id-type="pmid">31171848</pub-id><pub-id pub-id-type="pmcid">PMC6760626</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Guan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Spry</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Tjhin</surname><given-names>ET</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Kittikool</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Howieson</surname><given-names>VM</given-names></string-name>, <string-name name-style="western"><surname>Ling</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Starrs</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Duncan</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Burgio</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Saliba</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Auclair</surname><given-names>K</given-names></string-name></person-group>. <year>2021</year>. <article-title>Exploring heteroaromatic rings as a replacement for the labile amide of antiplasmodial pantothenamides</article-title>. <source>J Med Chem</source><volume>64</volume>:<fpage>4478</fpage>&#8211;<lpage>4497</lpage>. doi:<pub-id pub-id-type="doi">10.1021/acs.jmedchem.0c01755</pub-id><pub-id pub-id-type="pmid">33792339</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>de Vries</surname><given-names>LE</given-names></string-name>, <string-name name-style="western"><surname>Jansen</surname><given-names>PAM</given-names></string-name>, <string-name name-style="western"><surname>Barcelo</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Munro</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Verhoef</surname><given-names>JMJ</given-names></string-name>, <string-name name-style="western"><surname>Pasaje</surname><given-names>CFA</given-names></string-name>, <string-name name-style="western"><surname>Rubiano</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Striepen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Abla</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Berning</surname><given-names>L</given-names></string-name>, <etal>et al.</etal></person-group>. <year>2022</year>. <article-title>Preclinical characterization and target validation of the antimalarial pantothenamide MMV693183</article-title>. <source>Nat Commun</source><volume>13</volume>:<elocation-id>2158</elocation-id>. doi:<pub-id pub-id-type="doi">10.1038/s41467-022-29688-5</pub-id><pub-id pub-id-type="pmid">35444200</pub-id><pub-id pub-id-type="pmcid">PMC9021288</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gomtsyan</surname><given-names>A</given-names></string-name></person-group>. <year>2012</year>. <article-title>Heterocycles in drugs and drug discovery</article-title>. <source>Chem Heterocycl Comp</source><volume>48</volume>:<fpage>7</fpage>&#8211;<lpage>10</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10593-012-0960-z</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bhutani</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Joshi</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Raja</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Bachhav</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Rajanna</surname><given-names>PK</given-names></string-name>, <string-name name-style="western"><surname>Bhutani</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Paul</surname><given-names>AT</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>R</given-names></string-name></person-group>. <year>2021</year>. <article-title>U.S. FDA approved drugs from 2015-June 2020: a perspective</article-title>. <source>J Med Chem</source><volume>64</volume>:<fpage>2339</fpage>&#8211;<lpage>2381</lpage>. doi:<pub-id pub-id-type="doi">10.1021/acs.jmedchem.0c01786</pub-id><pub-id pub-id-type="pmid">33617716</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Meanwell</surname><given-names>NA</given-names></string-name></person-group>. <year>2017</year>. <part-title>A synopsis of the properties and applications of heteroaromatic rings in medicinal chemistry</part-title>, <comment>p</comment><fpage>245</fpage>&#8211;<lpage>361</lpage>. In <source>Advances in Heterocyclic Chemistry</source>. <publisher-name>Academic Press</publisher-name>.</mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ilardi</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Vitaku</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Njardarson</surname><given-names>JT</given-names></string-name></person-group>. <year>2014</year>. <article-title>Data-mining for sulfur and fluorine: an evaluation of pharmaceuticals to reveal opportunities for drug design and discovery</article-title>. <source>J Med Chem</source><volume>57</volume>:<fpage>2832</fpage>&#8211;<lpage>2842</lpage>. doi:<pub-id pub-id-type="doi">10.1021/jm401375q</pub-id><pub-id pub-id-type="pmid">24102067</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Feng</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>X</given-names></string-name></person-group>. <year>2016</year>. <article-title>Sulfur containing scaffolds in drugs: synthesis and application in medicinal chemistry</article-title>. <source>Curr Top Med Chem</source><volume>16</volume>:<fpage>1200</fpage>&#8211;<lpage>1216</lpage>. doi:<pub-id pub-id-type="doi">10.2174/1568026615666150915111741</pub-id><pub-id pub-id-type="pmid">26369815</pub-id><pub-id pub-id-type="pmcid">PMC4877035</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Beno</surname><given-names>BR</given-names></string-name>, <string-name name-style="western"><surname>Yeung</surname><given-names>KS</given-names></string-name>, <string-name name-style="western"><surname>Bartberger</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Pennington</surname><given-names>LD</given-names></string-name>, <string-name name-style="western"><surname>Meanwell</surname><given-names>NA</given-names></string-name></person-group>. <year>2015</year>. <article-title>A survey of the role of noncovalent sulfur interactions in drug design</article-title>. <source>J Med Chem</source><volume>58</volume>:<fpage>4383</fpage>&#8211;<lpage>4438</lpage>. doi:<pub-id pub-id-type="doi">10.1021/jm501853m</pub-id><pub-id pub-id-type="pmid">25734370</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ayati</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Emami</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Asadipour</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Shafiee</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Foroumadi</surname><given-names>A</given-names></string-name></person-group>. <year>2015</year>. <article-title>Recent applications of 1,3-thiazole core structure in the identification of new lead compounds and drug discovery</article-title>. <source>Eur J Med Chem</source><volume>97</volume>:<fpage>699</fpage>&#8211;<lpage>718</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ejmech.2015.04.015</pub-id><pub-id pub-id-type="pmid">25934508</pub-id></mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pasqualotto</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Thiele</surname><given-names>KO</given-names></string-name>, <string-name name-style="western"><surname>Goldani</surname><given-names>LZ</given-names></string-name></person-group>. <year>2010</year>. <article-title>Novel triazole antifungal drugs: focus on isavuconazole, ravuconazole and albaconazole</article-title>. <source>Curr Opin Investig Drugs</source><volume>11</volume>:<fpage>165</fpage>&#8211;<lpage>174</lpage>.<pub-id pub-id-type="pmid">20112166</pub-id></mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fox</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Saravolatz</surname><given-names>LD</given-names></string-name></person-group>. <year>2005</year>. <article-title>Nitazoxanide: a new thiazolide antiparasitic agent</article-title>. <source>Clin Infect Dis</source><volume>40</volume>:<fpage>1173</fpage>&#8211;<lpage>1180</lpage>. doi:<pub-id pub-id-type="doi">10.1086/428839</pub-id><pub-id pub-id-type="pmid">15791519</pub-id></mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jang</surname><given-names>HC</given-names></string-name>, <string-name name-style="western"><surname>Choi</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>HK</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Kang</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>KH</given-names></string-name>, <string-name name-style="western"><surname>Ryu</surname><given-names>PY</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>TH</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>YR</given-names></string-name>, <string-name name-style="western"><surname>Rhee</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Jung</surname><given-names>SI</given-names></string-name>, <string-name name-style="western"><surname>Choy</surname><given-names>HE</given-names></string-name></person-group>. <year>2014</year>. <article-title>In vivo efficacy of the combination of ciprofloxacin and cefotaxime against Vibrio vulnificus sepsis</article-title>. <source>PLoS One</source><volume>9</volume>:<elocation-id>e101118</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0101118</pub-id><pub-id pub-id-type="pmid">24978586</pub-id><pub-id pub-id-type="pmcid">PMC4076242</pub-id></mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hunt</surname><given-names>JT</given-names></string-name></person-group>. <year>2009</year>. <article-title>Discovery of ixabepilone</article-title>. <source>Mol Cancer Ther</source><volume>8</volume>:<fpage>275</fpage>&#8211;<lpage>281</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1535-7163.MCT-08-0999</pub-id><pub-id pub-id-type="pmid">19174552</pub-id></mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Eagling</surname><given-names>VA</given-names></string-name>, <string-name name-style="western"><surname>Back</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Barry</surname><given-names>MG</given-names></string-name></person-group>. <year>1997</year>. <article-title>Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir</article-title>. <source>Br J Clin Pharmacol</source><volume>44</volume>:<fpage>190</fpage>&#8211;<lpage>194</lpage>. doi:<pub-id pub-id-type="doi">10.1046/j.1365-2125.1997.00644.x</pub-id><pub-id pub-id-type="pmid">9278209</pub-id><pub-id pub-id-type="pmcid">PMC2042821</pub-id></mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lan</surname><given-names>CB</given-names></string-name>, <string-name name-style="western"><surname>Auclair</surname><given-names>K</given-names></string-name></person-group>. <year>2023</year>. <article-title>1,5,7-Triazabicyclo[4.4.0]dec-5-ene: an effective catalyst for amide formation by lactone aminolysis</article-title>. <source>J Org Chem</source><volume>88</volume>:<fpage>10086</fpage>&#8211;<lpage>10095</lpage>. doi:<pub-id pub-id-type="doi">10.1021/acs.joc.3c00913</pub-id><pub-id pub-id-type="pmid">37432197</pub-id></mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhou</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Ni</surname><given-names>SY</given-names></string-name>, <string-name name-style="western"><surname>Mei</surname><given-names>HB</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Pan</surname><given-names>Y</given-names></string-name></person-group>. <year>2015</year>. <article-title>Cyclization reaction of N -allylbenzothioamide for direct construction of thiazole and thiazoline</article-title>. <source>Tetrahedron Lett</source><volume>56</volume>:<fpage>4128</fpage>&#8211;<lpage>4130</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.tetlet.2015.05.047</pub-id></mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mykhailiuk</surname><given-names>PK</given-names></string-name></person-group>. <year>2019</year>. <article-title>Saturated bioisosteres of benzene: where to go next?</article-title><source>Org Biomol Chem</source><volume>17</volume>:<fpage>2839</fpage>&#8211;<lpage>2849</lpage>. doi:<pub-id pub-id-type="doi">10.1039/C8OB02812E</pub-id><pub-id pub-id-type="pmid">30672560</pub-id></mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lomer</surname><given-names>TR</given-names></string-name></person-group>. <year>1963</year>. <article-title>The crystal and molecular structure of lauric acid (form A)</article-title>. <source>Acta Cryst</source><volume>16</volume>:<fpage>984</fpage>&#8211;<lpage>988</lpage>. doi:<pub-id pub-id-type="doi">10.1107/S0365110X63002632</pub-id></mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ennis</surname><given-names>HL</given-names></string-name>, <string-name name-style="western"><surname>Lubin</surname><given-names>M</given-names></string-name></person-group>. <year>1964</year>. <article-title>Cycloheximide: aspects of inhibition of protein synthesis in mammalian cells</article-title>. <source>Science</source><volume>146</volume>:<fpage>1474</fpage>&#8211;<lpage>1476</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.146.3650.1474</pub-id><pub-id pub-id-type="pmid">14208575</pub-id></mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schneider-Poetsch</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Ju</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Eyler</surname><given-names>DE</given-names></string-name>, <string-name name-style="western"><surname>Dang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Bhat</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Merrick</surname><given-names>WC</given-names></string-name>, <string-name name-style="western"><surname>Green</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>JO</given-names></string-name></person-group>. <year>2010</year>. <article-title>Inhibition of eukaryotic translation elongation by cycloheximide and lactimidomycin</article-title>. <source>Nat Chem Biol</source><volume>6</volume>:<fpage>209</fpage>&#8211;<lpage>217</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nchembio.304</pub-id><pub-id pub-id-type="pmid">20118940</pub-id><pub-id pub-id-type="pmcid">PMC2831214</pub-id></mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chan</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Martin</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Liptrott</surname><given-names>NJ</given-names></string-name>, <string-name name-style="western"><surname>Siccardi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Almond</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Owen</surname><given-names>A</given-names></string-name></person-group>. <year>2017</year>. <article-title>Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation rates</article-title>. <source>Pharmacol Res Perspect</source><volume>5</volume>:<elocation-id>e00359</elocation-id>. doi:<pub-id pub-id-type="doi">10.1002/prp2.359</pub-id><pub-id pub-id-type="pmid">28971619</pub-id><pub-id pub-id-type="pmcid">PMC5625163</pub-id></mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Brand</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Strauss</surname><given-names>E</given-names></string-name></person-group>. <year>2005</year>. <article-title>Characterization of a new pantothenate kinase isoform from Helicobacter pylori</article-title><italic toggle="yes">.</italic><source>J Biol Chem</source><volume>280</volume>:<fpage>20185</fpage>&#8211;<lpage>20188</lpage>. doi:<pub-id pub-id-type="doi">10.1074/jbc.C500044200</pub-id><pub-id pub-id-type="pmid">15795230</pub-id></mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yun</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>CG</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>JY</given-names></string-name>, <string-name name-style="western"><surname>Rock</surname><given-names>CO</given-names></string-name>, <string-name name-style="western"><surname>Jackowski</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>HW</given-names></string-name></person-group>. <year>2000</year>. <article-title>Structural basis for the feedback regulation of Escherichia coli pantothenate kinase by coenzyme A</article-title>. <source>J Biol Chem</source><volume>275</volume>:<fpage>28093</fpage>&#8211;<lpage>28099</lpage>. doi:<pub-id pub-id-type="doi">10.1074/jbc.M003190200</pub-id><pub-id pub-id-type="pmid">10862768</pub-id></mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Das</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Bhor</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Surolia</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Vijayan</surname><given-names>M</given-names></string-name></person-group>. <year>2006</year>. <article-title>Invariance and variability in bacterial PanK: a study based on the crystal structure of Mycobacterium tuberculosis PanK</article-title>. <source>Acta Crystallogr D Biol Crystallogr</source><volume>62</volume>:<fpage>628</fpage>&#8211;<lpage>638</lpage>. doi:<pub-id pub-id-type="doi">10.1107/S0907444906012728</pub-id><pub-id pub-id-type="pmid">16699190</pub-id></mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Eyobo</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Brand</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Martynowski</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Tomchick</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Strauss</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>H</given-names></string-name></person-group>. <year>2006</year>. <article-title>Crystal structure of a type III pantothenate kinase: insight into the mechanism of an essential coenzyme A biosynthetic enzyme universally distributed in bacteria</article-title>. <source>J Bacteriol</source><volume>188</volume>:<fpage>5532</fpage>&#8211;<lpage>5540</lpage>. doi:<pub-id pub-id-type="doi">10.1128/JB.00469-06</pub-id><pub-id pub-id-type="pmid">16855243</pub-id><pub-id pub-id-type="pmcid">PMC1540032</pub-id></mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hong</surname><given-names>BS</given-names></string-name>, <string-name name-style="western"><surname>Yun</surname><given-names>MK</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>YM</given-names></string-name>, <string-name name-style="western"><surname>Chohnan</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Rock</surname><given-names>CO</given-names></string-name>, <string-name name-style="western"><surname>White</surname><given-names>SW</given-names></string-name>, <string-name name-style="western"><surname>Jackowski</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>HW</given-names></string-name>, <string-name name-style="western"><surname>Leonardi</surname><given-names>R</given-names></string-name></person-group>. <year>2006</year>. <article-title>Prokaryotic type II and type III pantothenate kinases: the same monomer fold creates dimers with distinct catalytic properties</article-title>. <source>Structure</source><volume>14</volume>:<fpage>1251</fpage>&#8211;<lpage>1261</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.str.2006.06.008</pub-id><pub-id pub-id-type="pmid">16905099</pub-id></mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nicely</surname><given-names>NI</given-names></string-name>, <string-name name-style="western"><surname>Parsonage</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Paige</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Newton</surname><given-names>GL</given-names></string-name>, <string-name name-style="western"><surname>Fahey</surname><given-names>RC</given-names></string-name>, <string-name name-style="western"><surname>Leonardi</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Jackowski</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mallett</surname><given-names>TC</given-names></string-name>, <string-name name-style="western"><surname>Claiborne</surname><given-names>A</given-names></string-name></person-group>. <year>2007</year>. <article-title>Structure of the type III pantothenate kinase from Bacillus anthracis at 2.0 A resolution: implications for coenzyme A-dependent redox biology</article-title>. <source>Biochemistry</source><volume>46</volume>:<fpage>3234</fpage>&#8211;<lpage>3245</lpage>. doi:<pub-id pub-id-type="doi">10.1021/bi062299p</pub-id><pub-id pub-id-type="pmid">17323930</pub-id><pub-id pub-id-type="pmcid">PMC2613803</pub-id></mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hong</surname><given-names>BS</given-names></string-name>, <string-name name-style="western"><surname>Senisterra</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Rabeh</surname><given-names>WM</given-names></string-name>, <string-name name-style="western"><surname>Vedadi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Leonardi</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>YM</given-names></string-name>, <string-name name-style="western"><surname>Rock</surname><given-names>CO</given-names></string-name>, <string-name name-style="western"><surname>Jackowski</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>HW</given-names></string-name></person-group>. <year>2007</year>. <article-title>Crystal structures of human pantothenate kinases. Insights into allosteric regulation and mutations linked to a neurodegeneration disorder</article-title>. <source>J Biol Chem</source><volume>282</volume>:<fpage>27984</fpage>&#8211;<lpage>27993</lpage>. doi:<pub-id pub-id-type="doi">10.1074/jbc.M701915200</pub-id><pub-id pub-id-type="pmid">17631502</pub-id></mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Tempel</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Smil</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Bolshan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Schapira</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>HW</given-names></string-name></person-group>. <year>2013</year>. <article-title>Crystal structures of Klebsiella pneumoniae pantothenate kinase in complex with N&#8208;substituted pantothenamides</article-title> . <source>Proteins</source><volume>81</volume>:<fpage>1466</fpage>&#8211;<lpage>1472</lpage>. doi:<pub-id pub-id-type="doi">10.1002/prot.24290</pub-id><pub-id pub-id-type="pmid">23553820</pub-id></mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Franklin</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Cheung</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Rudolph</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Burshteyn</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Cassidy</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gary</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Hillerich</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Yao</surname><given-names>ZK</given-names></string-name>, <string-name name-style="western"><surname>Carlier</surname><given-names>PR</given-names></string-name>, <string-name name-style="western"><surname>Totrov</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Love</surname><given-names>JD</given-names></string-name></person-group>. <year>2015</year>. <article-title>Structural genomics for drug design against the pathogen Coxiella burnetii</article-title> . <source>Proteins</source><volume>83</volume>:<fpage>2124</fpage>&#8211;<lpage>2136</lpage>. doi:<pub-id pub-id-type="doi">10.1002/prot.24841</pub-id><pub-id pub-id-type="pmid">26033498</pub-id></mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tjhin</surname><given-names>ET</given-names></string-name>, <string-name name-style="western"><surname>Howieson</surname><given-names>VM</given-names></string-name>, <string-name name-style="western"><surname>Spry</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>van Dooren</surname><given-names>GG</given-names></string-name>, <string-name name-style="western"><surname>Saliba</surname><given-names>KJ</given-names></string-name></person-group>. <year>2021</year>. <article-title>A novel heteromeric pantothenate kinase complex in apicomplexan parasites</article-title>. <source>PLoS Pathog</source><volume>17</volume>:<elocation-id>e1009797</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.ppat.1009797</pub-id><pub-id pub-id-type="pmid">34324601</pub-id><pub-id pub-id-type="pmcid">PMC8366970</pub-id></mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>H&#246;rtnagel</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Prokisch</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Meitinger</surname><given-names>T</given-names></string-name></person-group>. <year>2003</year>. <article-title>An isoform of hPANK2, deficient in pantothenate kinase-associated neurodegeneration, localizes to mitochondria</article-title>. <source>Hum Mol Genet</source><volume>12</volume>:<fpage>321</fpage>&#8211;<lpage>327</lpage>. doi:<pub-id pub-id-type="doi">10.1093/hmg/ddg026</pub-id><pub-id pub-id-type="pmid">12554685</pub-id></mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Leonardi</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>YM</given-names></string-name>, <string-name name-style="western"><surname>Lykidis</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Rock</surname><given-names>CO</given-names></string-name>, <string-name name-style="western"><surname>Jackowski</surname><given-names>S</given-names></string-name></person-group>. <year>2007</year>. <article-title>Localization and regulation of mouse pantothenate kinase 2</article-title>. <source>FEBS Lett</source><volume>581</volume>:<fpage>4639</fpage>&#8211;<lpage>4644</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.febslet.2007.08.056</pub-id><pub-id pub-id-type="pmid">17825826</pub-id><pub-id pub-id-type="pmcid">PMC2034339</pub-id></mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Alfonso-Pecchio</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Garcia</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Leonardi</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Jackowski</surname><given-names>S</given-names></string-name></person-group>. <year>2012</year>. <article-title>Compartmentalization of mammalian pantothenate kinases</article-title>. <source>PLoS One</source><volume>7</volume>:<elocation-id>e49509</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0049509</pub-id><pub-id pub-id-type="pmid">23152917</pub-id><pub-id pub-id-type="pmcid">PMC3496714</pub-id></mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dansie</surname><given-names>LE</given-names></string-name>, <string-name name-style="western"><surname>Reeves</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Miller</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Zano</surname><given-names>SP</given-names></string-name>, <string-name name-style="western"><surname>Frank</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Pate</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Jackowski</surname><given-names>S</given-names></string-name></person-group>. <year>2014</year>. <article-title>Physiological roles of the pantothenate kinases</article-title>. <source>Biochem Soc Trans</source><volume>42</volume>:<fpage>1033</fpage>&#8211;<lpage>1036</lpage>. doi:<pub-id pub-id-type="doi">10.1042/BST20140096</pub-id><pub-id pub-id-type="pmid">25109998</pub-id><pub-id pub-id-type="pmcid">PMC4948118</pub-id></mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Leonardi</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>YM</given-names></string-name>, <string-name name-style="western"><surname>Yun</surname><given-names>MK</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Zeng</surname><given-names>FY</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Cui</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Rock</surname><given-names>CO</given-names></string-name>, <string-name name-style="western"><surname>White</surname><given-names>SW</given-names></string-name>, <string-name name-style="western"><surname>Jackowski</surname><given-names>S</given-names></string-name></person-group>. <year>2010</year>. <article-title>Modulation of pantothenate kinase 3 activity by small molecules that interact with the substrate/allosteric regulatory domain</article-title>. <source>Chem Biol</source><volume>17</volume>:<fpage>892</fpage>&#8211;<lpage>902</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.chembiol.2010.06.006</pub-id><pub-id pub-id-type="pmid">20797618</pub-id><pub-id pub-id-type="pmcid">PMC2929395</pub-id></mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Subramanian</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Yun</surname><given-names>MK</given-names></string-name>, <string-name name-style="western"><surname>Yao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sharma</surname><given-names>LK</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>RE</given-names></string-name>, <string-name name-style="western"><surname>White</surname><given-names>SW</given-names></string-name>, <string-name name-style="western"><surname>Jackowski</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Rock</surname><given-names>CO</given-names></string-name></person-group>. <year>2016</year>. <article-title>Allosteric regulation of mammalian pantothenate kinase</article-title>. <source>J Biol Chem</source><volume>291</volume>:<fpage>22302</fpage>&#8211;<lpage>22314</lpage>. doi:<pub-id pub-id-type="doi">10.1074/jbc.M116.748061</pub-id><pub-id pub-id-type="pmid">27555321</pub-id><pub-id pub-id-type="pmcid">PMC5064008</pub-id></mixed-citation></ref><ref id="B72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Subramanian</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Rock</surname><given-names>CO</given-names></string-name>, <string-name name-style="western"><surname>Jackowski</surname><given-names>S</given-names></string-name></person-group>. <year>2019</year>. <article-title>Human pantothenate kinase 4 is a pseudo-pantothenate kinase</article-title>. <source>Protein Sci</source><volume>28</volume>:<fpage>1031</fpage>&#8211;<lpage>1047</lpage>. doi:<pub-id pub-id-type="doi">10.1002/pro.3611</pub-id><pub-id pub-id-type="pmid">30927326</pub-id><pub-id pub-id-type="pmcid">PMC6511746</pub-id></mixed-citation></ref><ref id="B73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Reed</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Lieb</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Nijhout</surname><given-names>HF</given-names></string-name></person-group>. <year>2010</year>. <article-title>The biological significance of substrate inhibition: a mechanism with diverse functions</article-title>. <source>Bioessays</source><volume>32</volume>:<fpage>422</fpage>&#8211;<lpage>429</lpage>. doi:<pub-id pub-id-type="doi">10.1002/bies.200900167</pub-id><pub-id pub-id-type="pmid">20414900</pub-id></mixed-citation></ref><ref id="B74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wu</surname><given-names>B</given-names></string-name></person-group>. <year>2011</year>. <article-title>Substrate inhibition kinetics in drug metabolism reactions</article-title>. <source>Drug Metab Rev</source><volume>43</volume>:<fpage>440</fpage>&#8211;<lpage>456</lpage>. doi:<pub-id pub-id-type="doi">10.3109/03602532.2011.615320</pub-id><pub-id pub-id-type="pmid">21962113</pub-id></mixed-citation></ref><ref id="B75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yoshino</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Murakami</surname><given-names>K</given-names></string-name></person-group>. <year>2015</year>. <article-title>Analysis of the substrate inhibition of complete and partial types</article-title>. <source>Springerplus</source><volume>4</volume>:<elocation-id>292</elocation-id>. doi:<pub-id pub-id-type="doi">10.1186/s40064-015-1082-8</pub-id><pub-id pub-id-type="pmid">26120509</pub-id><pub-id pub-id-type="pmcid">PMC4478191</pub-id></mixed-citation></ref><ref id="B76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kokkonen</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Beier</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mazurenko</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Damborsky</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Bednar</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Prokop</surname><given-names>Z</given-names></string-name></person-group>. <year>2021</year>. <article-title>Substrate inhibition by the blockage of product release and its control by tunnel engineering</article-title>. <source>RSC Chem Biol</source><volume>2</volume>:<fpage>645</fpage>&#8211;<lpage>655</lpage>. doi:<pub-id pub-id-type="doi">10.1039/d0cb00171f</pub-id><pub-id pub-id-type="pmid">34458806</pub-id><pub-id pub-id-type="pmcid">PMC8341658</pub-id></mixed-citation></ref><ref id="B77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Saliba</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Kirk</surname><given-names>K</given-names></string-name></person-group>. <year>2001</year>. <article-title>H<sup>+</sup>-coupled pantothenate transport in the intracellular malaria parasite</article-title>. <source>J Biol Chem</source><volume>276</volume>:<fpage>18115</fpage>&#8211;<lpage>18121</lpage>. doi:<pub-id pub-id-type="doi">10.1074/jbc.M010942200</pub-id><pub-id pub-id-type="pmid">11278793</pub-id></mixed-citation></ref><ref id="B78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Spry</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Saliba</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Strauss</surname><given-names>E</given-names></string-name></person-group>. <year>2014</year>. <article-title>A miniaturized assay for measuring small molecule phosphorylation in the presence of complex matrices</article-title>. <source>Anal Biochem</source><volume>451</volume>:<fpage>76</fpage>&#8211;<lpage>78</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ab.2013.12.010</pub-id><pub-id pub-id-type="pmid">24333332</pub-id></mixed-citation></ref><ref id="B79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Neese</surname><given-names>F</given-names></string-name></person-group>. <year>2012</year>. <article-title>The ORCA program system</article-title>. <source>WIREs Comput Mol Sci</source><volume>2</volume>:<fpage>73</fpage>&#8211;<lpage>78</lpage>. doi:<pub-id pub-id-type="doi">10.1002/wcms.81</pub-id></mixed-citation></ref><ref id="B80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Neese</surname><given-names>F</given-names></string-name></person-group>. <year>2022</year>. <article-title>Software update: the ORCA program system&#8212;Version 5.0</article-title>. <source>Wiley Interdiscip Rev Comput Mol Sci</source><volume>12</volume>. doi:<pub-id pub-id-type="doi">10.1002/wcms.1606</pub-id></mixed-citation></ref><ref id="B81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pettersen</surname><given-names>EF</given-names></string-name>, <string-name name-style="western"><surname>Goddard</surname><given-names>TD</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>Meng</surname><given-names>EC</given-names></string-name>, <string-name name-style="western"><surname>Couch</surname><given-names>GS</given-names></string-name>, <string-name name-style="western"><surname>Croll</surname><given-names>TI</given-names></string-name>, <string-name name-style="western"><surname>Morris</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Ferrin</surname><given-names>TE</given-names></string-name></person-group>. <year>2021</year>. <article-title>UCSF ChimeraX: structure visualization for researchers, educators, and developers</article-title>. <source>Protein Sci</source><volume>30</volume>:<fpage>70</fpage>&#8211;<lpage>82</lpage>. doi:<pub-id pub-id-type="doi">10.1002/pro.3943</pub-id><pub-id pub-id-type="pmid">32881101</pub-id><pub-id pub-id-type="pmcid">PMC7737788</pub-id></mixed-citation></ref><ref id="B82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Goddard</surname><given-names>TD</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>Meng</surname><given-names>EC</given-names></string-name>, <string-name name-style="western"><surname>Pettersen</surname><given-names>EF</given-names></string-name>, <string-name name-style="western"><surname>Couch</surname><given-names>GS</given-names></string-name>, <string-name name-style="western"><surname>Morris</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Ferrin</surname><given-names>TE</given-names></string-name></person-group>. <year>2018</year>. <article-title>UCSF ChimeraX: meeting modern challenges in visualization and analysis</article-title>. <source>Protein Sci</source><volume>27</volume>:<fpage>14</fpage>&#8211;<lpage>25</lpage>. doi:<pub-id pub-id-type="doi">10.1002/pro.3235</pub-id><pub-id pub-id-type="pmid">28710774</pub-id><pub-id pub-id-type="pmcid">PMC5734306</pub-id></mixed-citation></ref><ref id="B83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Meng</surname><given-names>EC</given-names></string-name>, <string-name name-style="western"><surname>Goddard</surname><given-names>TD</given-names></string-name>, <string-name name-style="western"><surname>Pettersen</surname><given-names>EF</given-names></string-name>, <string-name name-style="western"><surname>Couch</surname><given-names>GS</given-names></string-name>, <string-name name-style="western"><surname>Pearson</surname><given-names>ZJ</given-names></string-name>, <string-name name-style="western"><surname>Morris</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Ferrin</surname><given-names>TE</given-names></string-name></person-group>. <year>2023</year>. <article-title>UCSF ChimeraX: tools for structure building and analysis</article-title>. <source>Protein Sci</source><volume>32</volume>:<elocation-id>e4792</elocation-id>. doi:<pub-id pub-id-type="doi">10.1002/pro.4792</pub-id><pub-id pub-id-type="pmid">37774136</pub-id><pub-id pub-id-type="pmcid">PMC10588335</pub-id></mixed-citation></ref><ref id="B84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schaefer</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Ingman</surname><given-names>VM</given-names></string-name>, <string-name name-style="western"><surname>Wheeler</surname><given-names>SE</given-names></string-name></person-group>. <year>2021</year>. <article-title>SEQCROW: a ChimeraX bundle to facilitate quantum chemical applications to complex molecular systems</article-title>. <source>J Comput Chem</source><volume>42</volume>:<fpage>1750</fpage>&#8211;<lpage>1754</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jcc.26700</pub-id><pub-id pub-id-type="pmid">34109660</pub-id></mixed-citation></ref><ref id="B85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ingman</surname><given-names>VM</given-names></string-name>, <string-name name-style="western"><surname>Schaefer</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Andreola</surname><given-names>LR</given-names></string-name>, <string-name name-style="western"><surname>Wheeler</surname><given-names>SE</given-names></string-name></person-group>. <year>2021</year>. <article-title>QChASM : quantum chemistry automation and structure manipulation</article-title> . <source>WIREs Comput Mol Sci</source><volume>11</volume>. doi:<pub-id pub-id-type="doi">10.1002/wcms.1510</pub-id></mixed-citation></ref><ref id="B86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bannwarth</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ehlert</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Grimme</surname><given-names>S</given-names></string-name></person-group>. <year>2019</year>. <article-title>GFN2-xTB-an accurate and broadly parametrized self-consistent tight-binding quantum chemical method with multipole electrostatics and density-dependent dispersion contributions</article-title>. <source>J Chem Theory Comput</source><volume>15</volume>:<fpage>1652</fpage>&#8211;<lpage>1671</lpage>. doi:<pub-id pub-id-type="doi">10.1021/acs.jctc.8b01176</pub-id><pub-id pub-id-type="pmid">30741547</pub-id></mixed-citation></ref><ref id="B87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ehlert</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Stahn</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Spicher</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Grimme</surname><given-names>S</given-names></string-name></person-group>. <year>2021</year>. <article-title>Robust and efficient implicit solvation model for fast semiempirical methods</article-title>. <source>J Chem Theory Comput</source><volume>17</volume>:<fpage>4250</fpage>&#8211;<lpage>4261</lpage>. doi:<pub-id pub-id-type="doi">10.1021/acs.jctc.1c00471</pub-id><pub-id pub-id-type="pmid">34185531</pub-id></mixed-citation></ref><ref id="B88"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Breneman</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Wiberg</surname><given-names>KB</given-names></string-name></person-group>. <year>1990</year>. <article-title>Determining atom&#8208;centered monopoles from molecular electrostatic potentials. The need for high sampling density in formamide conformational analysis</article-title>. <source>J Comput Chem</source><volume>11</volume>:<fpage>361</fpage>&#8211;<lpage>373</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jcc.540110311</pub-id></mixed-citation></ref><ref id="B89"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Grabowski</surname><given-names>SJ</given-names></string-name></person-group>. <year>2004</year>. <article-title>Hydrogen bonding strength&#8212;measures based on geometric and topological parameters</article-title>. <source>J of Physical Organic Chem</source><volume>17</volume>:<fpage>18</fpage>&#8211;<lpage>31</lpage>. doi:<pub-id pub-id-type="doi">10.1002/poc.685</pub-id></mixed-citation></ref><ref id="B90"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Domaga&#322;a</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Grabowski</surname><given-names>SJ</given-names></string-name></person-group>. <year>2005</year>. <article-title>C-H...N and C-H...S hydrogen bonds--influence of hybridization on their strength</article-title>. <source>J Phys Chem A</source><volume>109</volume>:<fpage>5683</fpage>&#8211;<lpage>5688</lpage>. doi:<pub-id pub-id-type="doi">10.1021/jp0511496</pub-id><pub-id pub-id-type="pmid">16833901</pub-id></mixed-citation></ref><ref id="B91"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Castro</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Nicol&#225;s-V&#225;zquez</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Zavala</surname><given-names>JI</given-names></string-name>, <string-name name-style="western"><surname>S&#225;nchez-Viesca</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Berros</surname><given-names>M</given-names></string-name></person-group>. <year>2007</year>. <article-title>Theoretical study of intramolecular, CH-X (X = N, O, Cl), hydrogen bonds in thiazole derivatives</article-title>. <source>J Chem Theory Comput</source><volume>3</volume>:<fpage>681</fpage>&#8211;<lpage>688</lpage>. doi:<pub-id pub-id-type="doi">10.1021/ct600336r</pub-id><pub-id pub-id-type="pmid">26627385</pub-id></mixed-citation></ref><ref id="B92"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Paulini</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>M&#252;ller</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Diederich</surname><given-names>F</given-names></string-name></person-group>. <year>2005</year>. <article-title>Orthogonal multipolar interactions in structural chemistry and biology</article-title>. <source>Angew Chem Int Ed Engl</source><volume>44</volume>:<fpage>1788</fpage>&#8211;<lpage>1805</lpage>. doi:<pub-id pub-id-type="doi">10.1002/anie.200462213</pub-id><pub-id pub-id-type="pmid">15706577</pub-id></mixed-citation></ref><ref id="B93"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fischer</surname><given-names>FR</given-names></string-name>, <string-name name-style="western"><surname>Wood</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Allen</surname><given-names>FH</given-names></string-name>, <string-name name-style="western"><surname>Diederich</surname><given-names>F</given-names></string-name></person-group>. <year>2008</year>. <article-title>Orthogonal dipolar interactions between amide carbonyl groups</article-title>. <source>Proc Natl Acad Sci USA</source><volume>105</volume>:<fpage>17290</fpage>&#8211;<lpage>17294</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.0806129105</pub-id><pub-id pub-id-type="pmid">18981424</pub-id><pub-id pub-id-type="pmcid">PMC2582285</pub-id></mixed-citation></ref><ref id="B94"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Choudhary</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gandla</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Krow</surname><given-names>GR</given-names></string-name>, <string-name name-style="western"><surname>Raines</surname><given-names>RT</given-names></string-name></person-group>. <year>2009</year>. <article-title>Nature of amide carbonyl--carbonyl interactions in proteins</article-title>. <source>J Am Chem Soc</source><volume>131</volume>:<fpage>7244</fpage>&#8211;<lpage>7246</lpage>. doi:<pub-id pub-id-type="doi">10.1021/ja901188y</pub-id><pub-id pub-id-type="pmid">19469574</pub-id><pub-id pub-id-type="pmcid">PMC2811422</pub-id></mixed-citation></ref><ref id="B95"><label>95</label><mixed-citation publication-type="patent"><person-group person-group-type="author"><string-name name-style="western"><surname>Schalkwijk</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hermkens</surname><given-names>PHH</given-names></string-name>, <string-name name-style="western"><surname>Koen Jakob</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Bonnert</surname><given-names>RV</given-names></string-name></person-group>. <year>2020</year>. <article-title>Pantothenamide analogues</article-title>. <patent>WO2020141155A1</patent>, <comment>issued</comment></mixed-citation></ref><ref id="B96"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wittwer</surname><given-names>CT</given-names></string-name>, <string-name name-style="western"><surname>Schweitzer</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Pearson</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>WO</given-names></string-name>, <string-name name-style="western"><surname>Windham</surname><given-names>CT</given-names></string-name>, <string-name name-style="western"><surname>Wyse</surname><given-names>BW</given-names></string-name>, <string-name name-style="western"><surname>Hansen</surname><given-names>RG</given-names></string-name></person-group>. <year>1989</year>. <article-title>Enzymes for liberation of pantothenic acid in blood: use of plasma pantetheinase</article-title>. <source>Am J Clin Nutr</source><volume>50</volume>:<fpage>1072</fpage>&#8211;<lpage>1078</lpage>. doi:<pub-id pub-id-type="doi">10.1093/ajcn/50.5.1072</pub-id><pub-id pub-id-type="pmid">2816792</pub-id></mixed-citation></ref><ref id="B97"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Trager</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Jensen</surname><given-names>JB</given-names></string-name></person-group>. <year>1976</year>. <article-title>Human malaria parasites in continuous culture</article-title>. <source>Science</source><volume>193</volume>:<fpage>673</fpage>&#8211;<lpage>675</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.781840</pub-id><pub-id pub-id-type="pmid">781840</pub-id></mixed-citation></ref><ref id="B98"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Allen</surname><given-names>RJW</given-names></string-name>, <string-name name-style="western"><surname>Kirk</surname><given-names>K</given-names></string-name></person-group>. <year>2010</year>. <article-title>Plasmodium falciparum culture: the benefits of shaking</article-title>. <source>Mol Biochem Parasitol</source><volume>169</volume>:<fpage>63</fpage>&#8211;<lpage>65</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.molbiopara.2009.09.005</pub-id><pub-id pub-id-type="pmid">19766147</pub-id></mixed-citation></ref><ref id="B99"><label>99</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Jacot</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Meissner</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sheiner</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Soldati-Favre</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Striepen</surname><given-names>B</given-names></string-name></person-group>. <year>2014</year>. <part-title>Genetic manipulation of <italic toggle="yes">toxoplasma gondii</italic></part-title>. In <person-group person-group-type="editor"><string-name name-style="western"><surname>Weiss</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>K</given-names></string-name></person-group> (ed), <source>Toxoplasma gondii (Second Edition) The Model Apicomplexan - Perspectives and Methods</source>. <publisher-name>Elsevier Academic Press</publisher-name>, <publisher-loc>Burlington</publisher-loc>.</mixed-citation></ref><ref id="B100"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lambros</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Vanderberg</surname><given-names>JP</given-names></string-name></person-group>. <year>1979</year>. <article-title>Synchronization of Plasmodium falciparum erythrocytic stages in culture</article-title>. <source>J Parasitol</source><volume>65</volume>:<fpage>418</fpage>. doi:<pub-id pub-id-type="doi">10.2307/3280287</pub-id><pub-id pub-id-type="pmid">383936</pub-id></mixed-citation></ref><ref id="B101"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lundholt</surname><given-names>BK</given-names></string-name>, <string-name name-style="western"><surname>Scudder</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Pagliaro</surname><given-names>L</given-names></string-name></person-group>. <year>2003</year>. <article-title>Technical notes: a simple technique for reducing edge effect in cell-based assays</article-title>. <source>SLAS Discov</source><volume>8</volume>:<fpage>566</fpage>&#8211;<lpage>570</lpage>. doi:<pub-id pub-id-type="doi">10.1177/1087057103256465</pub-id><pub-id pub-id-type="pmid">14567784</pub-id></mixed-citation></ref><ref id="B102"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Johnson</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Dennull</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Gerena</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Lopez-Sanchez</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Roncal</surname><given-names>NE</given-names></string-name>, <string-name name-style="western"><surname>Waters</surname><given-names>NC</given-names></string-name></person-group>. <year>2007</year>. <article-title>Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening</article-title>. <source>Antimicrob Agents Chemother</source><volume>51</volume>:<fpage>1926</fpage>&#8211;<lpage>1933</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.01607-06</pub-id><pub-id pub-id-type="pmid">17371812</pub-id><pub-id pub-id-type="pmcid">PMC1891422</pub-id></mixed-citation></ref><ref id="B103"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vong</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Tam</surname><given-names>IS</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Auclair</surname><given-names>K</given-names></string-name></person-group>. <year>2012</year>. <article-title>Inhibitors of aminoglycoside resistance activated in cells</article-title>. <source>ACS Chem Biol</source><volume>7</volume>:<fpage>470</fpage>&#8211;<lpage>475</lpage>. doi:<pub-id pub-id-type="doi">10.1021/cb200366u</pub-id><pub-id pub-id-type="pmid">22217014</pub-id><pub-id pub-id-type="pmcid">PMC5177020</pub-id></mixed-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>